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INTRODUCTION 
Good health is our greatest asset.without good health We can hardly expect 
success in any walk of  life.Nowadays man is much more easily subjected  to diseases 
due to their sedentary life styleand environment. 
The ancient literature Manimekalai  which is the major work of the third 
sangam period composed by the Great  Tamil  poet Seethalaisathanaar is classified as 
one of the Five Great  epics. It contains many references of the philosophy and the 
principles of the siddhars  and the siddha system of medicine.  
According to the tradition, it was “Shiva” who unfolded the knowledge of 
siddha system of medicine to his  concert “parvathi” who handed it down to “Nandhi 
deva” and he  Conveyed this Knowledge  to the siddhars. “ Siddhar" is a tamil word 
that is derived from its root “Chit”which means perfection in life  or heavenly bliss. It 
generally refers to eight kinds  of supernatural powers attainable by man.Siddhars 
were the greatest scientists in ancient time. 
One of the famous saint Thirumoolar  from his Thirumanthiram said that 
mZtpy; mZtpid  Mjpg;gpuhid 
mZtpy; mZtpid  Mapuq; $wpl;L 
mZtpy; mZit mZf ty;yhh;fl;F 
mZtpy; mZit mZfYkhNk. 
- jpUke;jpuk; 1971 
mZf;fs; NjhWk; rptk; 
rptk; NjhWk; rpw;wk;gyk; 
The world is made up of atoms and lord shiva is found in each 
atom.Therefore,it is said that he is everywhere in this world.Siddha science considers 
nature and man are essentially one.Man is a part and parcel of the universal nature. 
Siddha system of medicine is based upon the 96 tha ththuvangal.Among them 
the pancha-boothas(the five elements Earth,Water,Space,Fire and Air)and the three 
uyir thathukkal(thee humours vadha,pitha,kapha) got prime importance.The 
disturbance in the equilibrium of the three humours ,cause the  disesase.It is explained 
by saint Thiruvalluvar in his kural.  
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kpfpDk;  FiwapDk; Neha;nra;Ak; EhNyhh; 
tspKjyh ntz;zpa %d;W. 
In the siddha system mostly  to treat a disease, the selection of drug will be 
initially  with  herbals. If the disease does not respond to that herbal medicine   then  
only  the physician may select a mineral or metal  based drug. 
“PPNtH ghU jiyghU kpQ;rpdf;fhy; nky;y; nky;y 
gw;g nre;Jhuk; ghNu”  . 
Siddha system deals with all aspects of human life,not only medicine.Siddha 
system is a medical science comprising of  all branches of specialities such as 
Alchemy, Philosophy,Yoga, Tantra, Astrology etc. Kuzhanthai Maruthuvam is one of 
the  branch of medical science of siddhars which deals with the disease  exclusive  for 
children, their essential nature,specially on the functional changes and 
treatment.Agasthiyar  said that there are 4448 diseases in this world. Diseases of the 
Skin account for a great deal  of misery, suffering, incapacity, and economic loss. 
Besides this,they are a great handicap in the society, because they  are visible.The 
prevalence of Atopic dermatitis, has increased over the past 30 years and at high risk 
of developing asthma and allergic rhinitis of those who will develop atopic dermatitis.  
The trial drug Poovarasu Nei(Internal medicine) taken by author  is comparatively 
safer than synthetic drugs .So,the author had taken the Balakarappan a skin disease , 
mentioned in the literature  Balavagadam  similar to the signs and symptoms of 
Atopic dermatitis, for her clinical  dissertation  work. 
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                                              AIM AND OBJECTIVES 
AIM:  
            To evaluate  the efficacy and safety of the siddha medicine “PoovarasuNei”in 
the treatment of “BalaKarappan”(Atopic Dermatitis) in children. 
OBJECTIVES: 
PRIMARY OBJECTIVE: 
 To study the efficacy of PoovarasuNei in the treatment of  BalaKarappan 
 (Atopic Dermatitis) 
 To study the safety of the trial medicine  PoovarasuNei. 
SECONDARY OBJECTIVE: 
  To have a detailed analysis of the safety of the drug through 
 Toxicity studies 
 Pharmacological studies 
 Physico chemical analysis. 
  To collect and review the ideas of‟ BalaKarappan mentioned in various 
siddha literature in the aspects of Definition,aetiologyand Clinical features. 
 To make a correlative study of the Siddha aspect and  Modern aspect of my 
study BalaKarappan. 
 To have an idea about the incidence of the disease with regard to 
age,sex,socio-economic status,history of food habits and drug ingestion. 
 To have an extensive study that how the disease alters the normal conditions 
which are dealt under MukkutraVerupadugal, Envagaithaervu, 
Udalthaathukkal, Paruvakaalangal, Neerkuri, Neikuri. 
 To use the possible modern parameters in the investigation of the disease,that 
enhances to observe the progress of the patient. 
 To have a clinical trial ,to find out  the efficacy of the trial medicine 
“PoovarasuNei” (Internal medicine) in the treatment of BalaKarappan 
(Atopic Dermatitis) in children. 
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3.1    SIDDHA ASPECTS 
ghy fug;ghd; 
ghy fug;ghd; vd;gJ gjpndl;L tifahd fug;ghd;fspy; xd;whFk;. ghy 
fug;ghd; Foe;ijfSf;F cz;lhFk; gpzp MFk;.  ghythflk; E}ypy; 
tpsf;fg;gl;Ls;s FwpFzq;fspd; mbg;gilapy; Nehapidf; fzpj;J> rpj;j 
kUj;Jt Kiwj; Njh;Tfshd Kf;Fw;w NtWghLfs;> VOtif clw;jhJf;fs;> 
Fw;wq;fspd; jd;dpiytsh;r;rp> Ntw;Wepiy tsh;r;rp> gpzpawpKiwik> 
vz;tifj;Njh;Tfspd; mbg;gilapy; Nehapid Muha;e;J mjw;fhd gpzpePf;f 
KiwAk;> Neha; tuhky; jLf;Fk; topfSk; ,jpy; tpsf;fg;gl;Ls;sd. 
NtWngah;fs; 
 thiy fug;ghd;  
ghy fug;ghd; 
fug;ghd; Neha; ,ay; 
 clypy; jpkph;> jpdT> nrhwp> Gz;> jbg;G> ntbg;G> ePHf;frpjy; Mfpa 
FwpFzq;fis cz;lhf;fp clk;gpd; ,aw;if epwj;ij NtWgLj;Jk; Neha; 
        - ghythflk; 
 cly; KOtJk; Gz;> jbg;G ,uzj;ij cz;lhf;fp nfhg;Gsq;fs; fz;L 
Njhypd; epwj;ij NtWgLj;jp rpy Ntis ntbg;G> ePH frpjiy cz;lhf;fp 
twl;rpia Vw;gLj;Jk; Njhiyg; gw;wpa ,uz Neha;.  
- gps;is gpzp kUj;Jtk; ,uz;lhk; ghfk; 
Neha; tUk; gUtk; 
 Foe;ijfsJ jhyg; gUtk; Kjy; tUifg;gUtk; tiuAs;s ehd;F 
gUtq;fspYk; fug;ghd; Neha; Foe;ijfSf;F cz;lhff;$Lk;. 
  
,ak;GjpkpH fha;r;ry; ,aq;Fe; jpul;rp 
jaq;F fze;Njhd;We;jhd; fug;ghd; - eak;glNt 
te;J}Wk; khf;fzj;jpy; thjf;fug;ghd; 
       - ghythflk; 
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 ghYz;Zk; gUtk; Kjy; ghYk; NrhW cz;Zk; gUtk; tiu 
Foe;ijfisj; jhf;FfpwJ. 
     - gps;isg;gpzp kUj;Jtk; ,uz;lhk;ghfk; 
 
Foe;ijfis Neha; tijf;Fk; ehs; 
fowhd fug;ghd;jhd; gpwtp Nehf;fpf; 
fz;lKjy; ehs;njhlq;fpj; jpq;fs; %d;W 
Gowhd Fotpfis tijf;Fk; fhyk;................. 
- gjpnzz; rpj;jh;fs; itj;jpa rpy;yiuf; Nfhit  
Nkw;fhZk; Mjhu E}y;fspd; mbg;gilapy; ghy fug;ghd; vDk; Neha; 
Foe;ijfspd; jhyg; gUtk; Kjy; tUifg; gUtk; tiu tUnkd $wg;gbDk;> 
ghyfug;ghd;  ghyh;fspy; 1 Kjy; 12 taJ tiu njhlh;fpd;wJ. 
Neha; tUk; top 
ghythflk; E}ypy; 
  “gpwe;jehs; gps;isf;Fj; jhNd ed;wha; 
   gpjhthNy gpzpAlypd; NkNy Njhd;Wk; 
  rpwe;j gpzp fzkhe;jk; fug;;ghd; Njhlk;  
   jPjhF kf;fuq;fs; fpue;jp Kd;dhk; 
  mwe;jiof;F kUe;jwpiQahdhw; jPUk; 
   mJtd;wp kUe;jwpQdhdhw; jPUk; 
  jpwe;njwpe;J ghHj;JtpL rpW gps;isf;Fr; 
   rPuhf tU Neha;fs; nrg;gf; NfNs” 
 Rf;fpy RNuhzpjk; fye;J fU cz;lhFk; NghJ> je;ijapd; czthjp 
nray;fspd; Fw;wj;jpdhy; rpRtpw;F gy gpzpfs; jhapd; tapw;wpypUe;J 
ntspte;jTlNdNa Njhd;Wk;.  mt;thW Njhd;Wk; gpzpfspy; fug;ghDk; 
xd;whFk;.  vdNt fug;ghd; fUtpy; Njhd;Wk; Neha; MFk;. 
 
 
6 
 
  ngUFQ; Nrhs kpWq;Fk; ngUq;fk;G 
  tuF fhUld; thioapd; fhnahL 
  ciunfhs; ghfw; nfspw;W kPd; cz;bby; 
  tphpt jha;f; fug;ghD kpFe;jNj 
        - ghythflk; 
 Nrhsk;> fk;G> tuF> fhuhprp> thiof;fha;> ghfw;fha;> nfspw;W kPd; 
Nghd;w czthjp nray;fspdhy; fug;ghd; gpzp cz;lhff;$Lk;> NkYk; ,e;j 
czthjpfis gpzp cs;s NghJ vLj;Jf; nfhz;lhy; gpzp kpFjpg;gLk;. 
gps;isg;gpzp kUj;Jt E}ypy; 
“Vohd fug;ghd; jd; cw;gj;jp NfS 
Naj;jklh khq;fp rq;fs; Grpf;ifahYk; 
$ohd fk;G jpid tuF rhik 
nfhbjhd fpoq;Ftif aUe;jyhYk; 
ghohd ngz;kha;if jd;dpy; rpf;fp 
ghq;fhd tpfj;jhd Kaw;rpahYk; 
jhohd gz;lfq;fs; rikj;Jj; 
  jpd;dy; jhf;FNk fug;ghdpd; rhay; jhNd” 
khkprq;fs; Grpg;gjhYk;> fk;G> jpid> tuF> rhik> fpoq;F tiffis 
cz;gjpdhYk;> ngz; ,r;ir cilath;fshYk;> jho;thd gz;lq;fis 
rikj;J cz;gjpdhYk; fug;ghd; gpzpahdJ cz;lhfpwJ vd rpj;j kUj;Jt 
E}y;fs; $Wfpd;wd. 
kjiy Neha; E}ypy; - njhFjp –I 
  fug;ghd; je;ijahy; Nkfj;jhYk; 
   fUthd Njh\q;fs; tp\j;jpdhYk; 
  Nfhg;ghd fpue;jpapdhy; fh;kj;jhYk; 
   nfhq;ifghy; Fbj;jke;j fpUkpahYk; 
  jhg;ghd fug;gdJ mZfpf;nfhs;Sk; 
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   rj;jpa kha;r; nrhy;YfpNwd; jfik NfS 
  Vw;ghd fug;ghdJ <nuhd;g jhFk; 
   ,jpd;NkNy mTjq;fs; FwpAk; NfNs. 
      ifnaOj;Jg;gpujp 98-150-151 
 Nkfj;jpdhy; ghjpf;fg;gl;l je;ijapd; Njh\Ks;s tpe;Jtpdhy; 
fUcw;gj;jpahFk; NghJ Njhlj;jpdhy; ghjpf;fg;gLfpd;wJ. gpd;G fU 
Foe;ijahf ntspNa te;J mj;Njhlk; njhlh;fpd;wJ. Mfhu NtWghLfspdhy; 
cz;lhd Njh\k; cs;s jha;ghiy Foe;ij mUe;jp ke;jKz;lhfp> mg;NghJ 
cz;lhFk; fpUkpfshYk; fug;ghd; cw;gj;jp Mfpwnjd E}y;fs; $Wfpd;wd. 
Mj;kul;rhkph;jnkd;Dk; itj;jpa rhu rq;fpufk; E}ypy; 
ghNu Foe;ijg; gpzpf;Fwpg;Gk; gfUk;gl;rp Njh\Kld; 
NeNu khe;jk; gjpndl;Lk; NeUq;fpue;jp jd;FzKk; 
rPNuGzh;r;rpf; fhe;jyJQ; rpwe;jfh;g;gr; #LKjy; 
NeNukhe;j uwpantd;W epiwahAiuj;j jpJthNk 
 fpue;jp> gl;rp Njh\k;> khe;jk;> fzk;> fug;ghd;> mf;fuk;> 
nrt;thg;G>njhz;ilf;fl;L>it#hp Kjyhd mNef Nuhfq;fs; Foe;ijfSf;F 
rk;gtpf;fpd;wJ. khe;jk; jhapd; Kiyg;ghyhYk;> fzk; fh;g;gr; #l;bdhYk; 
kw;wg; gpzpfshd fug;ghd; Nghd;wit jha; je;ijapd; Gzh;r;rpapdh nyOe;j 
#l;bdhY Kz;lhfpwJ. 
mfj;jpah; fd;k fhz;lk; 300 E}ypy; 
  cz;iknad;w fug;ghNdhL tz;L fbFl;l 
  KfpYs;NshHf;fpJ te;j cz;ikNfS 
  jd;ik nad;w jpy;yhk Xjhrpdq;fs; Ngr 
  rw;FUit J}ldpj;j rz;lhsj;jhy; 
td;iknad;w topapNy Ks; spl;L itj;jy; 
  kue;jiofs; G+Tjpu tbj;j ghtk; 
  ngz;ikapNy tz;Lfb tplKQ; Nrh;j;J 
  gpyj;j nrhwp Fl;lkJ gpyj;j thNw” 
 Nkw;fhZk; nra;As; ciug;gJ ahnjdpy;> tz;LfbapdhYk;> fd;k 
tpidfspdhYk; fug;ghd; gpzp cz;lhfpd;wJ vd mwpag;gLfpwJ. 
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guuhrNrfu E}ypy; 
  Ntff; fhw;wjpdh; gidnty;yj;jhy; 
   ghf kpf;fyhd; Nkjpg; ghntapyhy; 
  jhfkhdp tUf;f jprhHjyhy; 
   Nkhf thio tOjiy Ks;spf;fhs; 
  fhAk; gy;yplj; jhw;Ruj; jhw;fspy; 
   vAk; tz;nlypahy; tUNk  Jntsp 
  Fb ey;ywpthd vUtpdhH 
   ahd khdfug;ghd; tiffNs. 
 mjpfkhd fhw;W> mjpf ntapy;> gidnty;yk;> thiof;fha;> tOjiy> 
Ks;spf;fha; KjyhditfshYk; tz;L> vyp Kjypait fbj;jyhYk; fug;ghd; 
gpzp cz;lhfpd;wJ. 
Nuhf eph;za rhuk; E}ypy; 
 Mfhuk; gprFjy;> gOf;fhj goq;fs;> gUg;G tiffs;> gytpj 
khkprq;fs;> m[Puz t];Jf;fs; ,itfis Foe;ijapd; jha; Grpg;gjhy; 
Foe;ijfSf;F fug;ghd; Nuhfq;fs; tUfpd;wJ. 
Neha; vz; 
 ghy thfl E}ypy; $wg;gl;Ls;s fug;ghdpd; Neha; vz; - 18 
  Kj;Njhl khpA+J #iy 
   Kd;Dntb kz;ilnghhp rl;il 
  rw;NwhL fUiknahL nrk;ik 
   jdpf;nfhs;sp NjhlnkhL thiy 
  Kw;Nwhy;t ul;rpnahL tPq;fy; 
   %hptUk; gjpndl;L tifahk; 
  nfhj;jhd fug;ghd;f nsd;W 
   $wpdhH gz;ilNah uhkhy; 
  nrq;fug;ghd; mdy;fug;ghd; jhDk; kz;ilr; 
   rpuq;Fgz;Zk; mhpfug;ghd; nghhpf ug;ghd; 
  mq;fkjp nyOfug;ghd; jhD kpf;f 
   msuhk;cjp uf;fug;ghd; fl;bNahL 
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  nghq;fkha; tPq;fp fug;gh De;jhd; 
   Gfyhpa rl;iljb ntbfug;ghd; 
  rpq;fKf vhpfug;ghd; thj gpj;jr; 
   Nrj;Jke;Njh Nlfug;ghd; gjpndl;lhNk. 
1. thjfug;ghd; 
2. mow;fug;ghd; 
3. Iaf;fug;ghd; 
4. mhpfug;ghd; 
5. CJfug;ghd; 
6. #iy fug;ghd; 
7. ntbfug;ghd; 
8. kz;ilf; fug;ghd; 
9. nghhp fug;ghd; 
10. rl;il fug;ghd; 
11. XL fug;ghd; 
12. fUq;fug;ghd; 
13. nrq;fug;ghd; 
14. nfhs;spf;fug;ghd; 
15. Njhlf;fug;ghd; 
16. thiy fug;ghd; (ghy fug;ghd;) 
17. tus; fug;ghd; 
18. tP;q;F fug;ghd; 
fug;ghd; jPUk; jPuh epiy- 
gjpndd; tif fug;ghd;fspy; nfhs;spf;fug;ghd; kw;Wk; nrq;fug;ghd; 
jPuhJ.gjpdhW fug;ghd; jPUk;. ghy fug;ghd; jPUk; gpzp MFk;. 
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NtW E}y;fspy; fug;ghdpd; tiffs; 
 mfj;jpah; 2000    - 66 
 FUehb rh];jpuk;    - 85 
 b.tp.rhk;gtrptk; gps;is mfuhjp  - 29 
 gps;is gpzp kUj;Jt E}y;  - 54 
 ghy itj;jpa Nghjpdp E}y;  -  9 
 A+fp itj;jpa rpe;jhkzp   -  7 
 mfj;jpah; uz E}y;    - 80 
 Fk;gKdp ghythflk;   - 18 
 mfj;jpah; 2000> 3-k; ghfk;   -  6 
,t;thW gy;NtW E}y;fspy; fug;ghdpd; tiffs; gythW 
$wg;gl;bUe;jhYk; ghythfl E}ypy; $wg;gl;Ls;s 18 tif fug;ghd;fspy; “ghy 
fug;ghd;” Ma;thshpd; Ma;Tf;fhf vLj;Jf; nfhs;sg;gl;Ls;sJ 
 
thiy fug;;ghdpd;; FwpFzq;;fs;; 
ghythfl E}ypy; 
  fhyJ fLf;FQ; re;J 
   fz;lKk; ntbj;Jg; Gz;zha; 
  VyNt fbtplk; Nghy; 
   ,Uj;Jgd; dPH Nghy; gha;e;J 
Nfhykha; tw;wp ehWk; 
   FotpA nkhLq;F khfpy; 
khyUq; Foyha; thy     
  fug;ghd;nra; thW jhNd 
fhy;fuq;f NshL re;J 
  Nktypfshfpa fbtplq;fs; Nghy 
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Nky;jbj; jjpYk; ePH gwpe;J 
  kfs;nka; nahLq;fp apuzq;fsha; 
%y ehspDs; njhz;ilNahL 
  tpuzq;f shfpKjph; ntg;gkhk; 
thiyahd fug;ghdpnjd;wTk; 
  jq;fSQ; rpwpJ itj;jpNl 
gzpthd tpfhuKw; wNdfq; $wha; 
           guguj;J Njfnky;yhe; nrhwpNgh yhfp 
gpzpahd rhiuAly; NghNy fhZk; 
  gpzpthapy; tplye;jhd; cjpuk;Nghy 
jpdpahd Fiytw;wp jpUt ope;J 
  jprjhJ gPlnky;yhk; eLe Lq;fp 
tdpahd ,f;Fzq;fs; fz;l jhdhy; 
  thyfug; ghdJntd; wpak;g yhNk 
                                gf;fk; vz; - 398 
ghly; tpsf;fk;     
guguntd;W Njfnky;yhk;              
nrhwpNghy; cz;lhFk;.                     
- Atopic Dermatitis is a chronic pruritic 
inflammation of the skin 
rhiuAly; NghNy fhZk;         - Xerosis is the hall mark of Atopic Dermatitis 
fhy;> fuq;fs;> re;J> fz;lk; 
,t;tplq;fspy; cz;lhFk;  
- Common site of Atopic Dematitis is folds of the 
elbows, behind the knees, flexural surfaces of the 
upper and lower limbs and sides of the neck. 
fbtplq;fs; Nghy 
jbj;Jf;fhZk;   
- Atopic dermatitis is a chronic inflammatory skin 
condition characterised by itchy papules, 
papulovesicular lesions consists of erythema and 
discrete confluent oedematous papules. 
fbtplq;fspy; gd;dPH Nghy  Papules are intensely itchy resulting in oozing 
12 
 
ePHgwpe;J mit tw;wp ehWk;.  
gpzpthapy; tplrykhdJ 
cjpuk; Nghd;W tbAk;. 
and may become exudative and crusted as a 
result of rubbing. 
,uzq;fsha; khWk;.  Abrasion of the epidermis due to secondary 
bacterial and viral infections. 
Foe;ijapd; nka;nahLq;Fk;  In Infantile eczema child is irritable and weak. 
njhz;ilapy; tpuzk; 
cz;lhFk;   
 Atopic Dermatitis is associated with a personal 
or family history of hay fever, asthma and 
allergic rhinitis.  In allergic diseases intermittent 
dry cough resulting in inflammation of the throat. 
 
Kf;Fw;w NtWghLfs; 
 thjf; Fw;wkhdJ Ntw;Wepiy tsh;r;rpailtijj; njhlh;e;J fgf; 
Fw;wk; Nflile;J ,Wjpapy; gpj;j Fw;wk; jd;dpiyapypUe;J gpwo;tjhy; 
fug;ghd; gpzp cz;lhfpd;wJ. 
Kf;Fw;wq;fSk; mtw;wpd; nra;njhopYk; 
thjk;  
thjkhdJ ,aw;if epiyapy; epd;W Cf;fKz;lhf;fy;> kyk; Kjypa 
gjpdhd;F tpiuTfis ntspg;gLj;Jjy;> rhuk; Kjypa VO 
clw;fl;Lfl;LfSf;Fk; xj;j epfo;r;rpiaj; juy;> Ik;nghwpfl;F td;ikiaf; 
nfhLj;jy; Mfpa njhopy;fisg; GhpAk; 
tsp clypy; nra;njhopy; 
 ePHg;girapd;ik (twl;rp) 
 ,isj;jy; 
 kyk; milgLjy; 
 Njhy; fWj;Jf; fhzy; 
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thjj;jpd; 
tiffs 
nra;njhopy; 
ghy fug;ghd; gpzpapy; 
Fw;wq;fspd; epiy 
ghjpg;G/,ay;G 
gpuhzd; 
%r;Rtply;> thq;fy;> Jk;ky;> Vg;gk; 
tply;> fhwpAkpo;jy;> cz;Zk; czit 
nrhpf;fg; gz;Zk;. 
ghjpg;G 
mghdd; 
md;drhuj;ij Nru Ntz;ba ,lq;fspy; 
Nrh;g;gpf;Fk;. ntz;zPH> ehjk;> kyk;> 
rpWePH> fU ,tw;iw ntspg;gLj;Jk; 
ghjpg;G - kyf;fl;L 
cz;lhjy; 
tpahdd; 
cz;Zk; cztpd; rhuj;ij 
mt;tt;tplq;fspy; epiwg;gpj;J cliyf; 
fhf;Fk;. elj;jy;> cly; cWg;Gfis 
mirj;jy; Mfpaitfis GhpAk;. 
ghjpg;G 
cjhdd; 
cztpd; rhuj;ij $bapUe;J mq;NfNa 
epWj;Jk;.  mij ntspg;gLj;jpAk; 
fyf;fpAk; tUjy; nraa;Ak;.  
ghjpg;G - cly;td;ik> 
cly; epwk;> cly; xsp 
Fiwjy;. 
rkhdd; 
kw;w thAf;fis kpQ;rnthl;lhkw; 
klf;fpr; rhpg;gLj;jpr; Nrur;nra;Ak;.  
czTg;nghUl;fs; nrhpg;gjw;Fhpa jPia 
tpUj;jp nra;J rhuj;ijAk;> jpg;gpiaAk; 
gphpj;J rhuj;ij clypd; vy;yhg; 
ghfq;fSf;Fk; gfph;e;J nfhLj;J 
tsh;f;Fk;. 
ghjpg;G - kw;w 
Fw;wq;fs; ghjpg;G 
ehfd; 
vy;yhf; fiyfisAk; fw;Fk;gb 
mwpit vOg;Gk; kaph;fisr; rpypHf;f 
nra;Ak;. 
,ay;G 
$Hkd; 
kdjpypUe;J fpsk;gp fz;zpy; epd;W 
,ikiaf; nfhl;Ltpf;Fk;.  nfhl;lhtp 
tplg;gz;Zk;.  thia %lr; nra;Ak;. 
,ay;G 
fpUfud; 
ehtpypUe;J ehtpw;frpitAk;> ehrpapw; 
frpitAk; cz;lhf;Fk;.  kpFe;j 
grpiaAz;lhf;fr; nra;Ak; 
ghjpg;G 
Njtjj;jd; 
Nrhk;giyAk;> cly; Khpj;jiyAk; 
cz;lhf;Fk;. rz;il nfhs;sy;> jh;f;fk; 
Ngry;> kpFe;j Nfhgk; 
Kjypatw;iwAz;lhf;Fk; 
ghjpg;G – cly;NrhHT 
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jdQ;nrad; 
%f;fpypUe;J jbj;J clk;G KOikAk; 
tPq;fg;gz;Zk;.fhjpy; fly; NghypiuAk;. 
,we;Jtpbd; fhw;nwy;yhk; ntspg;gl;l 
gpd;dh; %d;whtJ ehspy; jiy ntbj;j 
gpd; jhd; NghFk;. 
        -       
 
 
gpj;jk; 
 ,aw;if epiyapdpd;W nrhpg;gpj;jy;> ntk;ik> ghHit> grp> ePHNtl;if> 
Rit> xsp> epidg;G> mwpT> td;ik> nkd;ik ,itfis cz;lhf;fp 
clw;Fj;Jiz GhpAk;. 
moy; clypy; nra;njhopy; 
 clypy; ntg;gk; cz;lhjy;>  nkypT> vhpT ,itAz;lhjy;. 
 nre;ePH jd; mstpy; kpFjy 
moypd; 
gphpTfs; 
nra;njhopy; 
ghy fug;ghd; 
gpzpapy; 
Fw;wq;fspd; epiy 
ghjpg;G/,ay;G 
mdw;gpj;jk; 
jPapd; Fzj;ij kpFjpahfg; ngw;W ePH 
tbtKs;s nghUs;fis twsr; nra;J 
cz;l czTg; nghUs;fisr; nrhpf;Fk;gb 
nra;Ak;. 
ghjpg;G 
,uQ;rfg; 
gpj;jk; 
cztpypUe;J gphpe;Jz;lhd rhWf;Fr; 
nre;epwj;ijj; jUfpwJ. 
ghjpg;G 
rhjfg; 
gpj;jk; 
epiwNtw;Wk; gz;GilaJ.  tpUg;gkhd 
njhopiyr; nra;J Kbf;Fk;. 
,ay;G 
MNyhrfg; 
gpj;jk; 
fz;fspy; tho;e;J nfhz;L vy;yhg; 
nghUs;fspd; tbtj;ijAk; mwpjyhfpa 
fhhpaj;ijr; nra;Ak;. 
,ay;G 
gpuhrfg; 
gpj;jk; 
NjhYf;F xspiaj; jUk; gz;GilaJ.  
Njhypy; tho;e;J nfhz;L NjhYf;F 
xspiaf; nfhLj;J mij xspur; nra;Ak;. 
 
ghjpg;G – Njhypy; 
xsp Fd;wy;> 
Njhypy; epwkhw;wk; 
cz;lhjy;. 
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Iak; 
,aw;if epiyapy; epd;W epiyj;jy;> grp> ePHNtl;if> Jauk;> fyf;fk;> 
ntg;gk; ,itfisg; nghWj;Jf; nfhs;Sjy;> fPy;fspd; mikg;gpw;F td;ik 
jUjy; Mfpa njhopy;fisg; GhpAk;. 
Iak; clypy; nra;njhopy; 
 nrhwp (jpdT) 
 Cz;tpiutpy; nrhpahik 
 njhopy; Ghptjpy; $h;ikapd;ik 
 nea;g;G 
 td;ik. 
Iaj;jpd; 
gphpTfs; 
nra;njhopy; 
ghy fug;ghd; gpzpapy; 
Fw;wq;fspd; epiy 
ghjpg;G/,ay;G 
mtyk;gfk; 
EiuaPuypy; ,Ue;J nfhz;L> jkufj;jpw;F 
mbg;gilaha; ,Ue;J kw;w ehd;F 
Iaq;fl;F gw;Wf;NfhlhapUj;jy; 
ghjpg;G 
fpNyjfk; 
,iug;igapypUe;J nfhz;L cz;zg;gl;l 
czTg; nghUs;fis <ug;gLj;jp 
nkj;njdr; nra;Ak; njhopiyg; GhpAk;. 
ghjpg;G 
Nghjfk; 
,J Ritg; nghwpahfpa ehtpdpd;W 
cz;Zfpw Ritfis mwptpf;Fk; 
njhopiyg; GhpAk; 
,ay;G 
jw;gfk; 
,J jiyapdpd;W fz;fSf;F 
FspHr;rpiaj; jUk; 
,ay;G 
re;jpfk; 
G+l;Lfspy; epd;W ,aw;ifaha; vy;yhf; 
fPy;fisAk; xd;Nwhnlhd;W nghUj;jpj; 
jsur; nra;J nfhz;bUf;Fk; 
,ay;G 
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VO clw; 
jhJf;fs; 
nra;njhopy; 
fug;ghd; gpzpapy; 
jhJf;fspd; epiy 
ghjpg;G/,ay;G 
rhuk; 
cliyAk;> kdijAk; Cf;FKwr; 
nra;tJ 
ghjpg;G - Njhy; 
RuRug;giljy; 
nre;ePH 
mwpT> td;ik> xsp> nrUf;F> xyp 
,itfis epiyf;fr; nra;tJ 
ghjpg;G – twl;rp 
Cz; 
clypd; cUtj;ij mjd; 
njhopw;fpzq;f mikj;jYk; vd;ig 
tsHj;jYkhk;. 
 ghjpg;G 
nfhOg;G 
xt;NthH cWg;Gk; jj;jk; nraiy 
,aw;Wk; nghOJ fbdkpd;wp ,aq;f 
mtw;wpw;F nea;g;Gg;gir Cl;b 
cjtpGhptJ. 
ghjpg;G - nea;g;Gj; 
jd;ikapd;ik 
 
vd;G 
cliy xOq;Fgl epWj;jp itj;jy;> 
nkd;ikahd cWg;Gfisg; 
ghJfhj;jy;> cly; mirtpw;F 
mbg;gilahapUj;jy; Mfpa 
njhopy;fisg; GhptjhFk;. 
,ay;G 
%is 
vd;Gf;Fs; epiwe;J mitfSf;F 
td;ikAk; nkd;ikAk; jUtJ. 
,ay;G 
Rf;fpyk;/RNuhzpjk; 
jd;idnahj;j cUtg; ngUf;fpw;F 
,lkhfpa fUj; Njhw;wj;jpw;F 
Kjyha; epw;gJ 
,ay;G 
 
Kf;Fw;wq;fSk; gUtf; fhyq;fSk; 
jd;dpiy tsh;r;rp: 
 Kf;Fw;wq;fSk; jj;jk; ,lq;fspy; tsh;r;rpailtNj jd;dpiy 
tsh;r;rpahFk;. 
Ntw;Wepiy tsh;r;rp: 
 tsh;r;rpaile;j Kf;Fw;wq;fs; jj;jk; ,lk; tpl;L kPwp Ntw;wplq;fspw; 
guTkhapd; mJ Ntw;Wepiy tsh;r;rpahFk;. 
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fhHfhyk;  - Mtzp> Gul;lhrp  
$jph;fhyk;;  - Ig;grp> fhHj;jpif 
Kd;gdpfhyk;  - khHfop> ij   
gpd;gdpfhyk;  - khrp> gq;Fdp  
,sNtdpy; fhyk; - rpj;jpiu> itfhrp  
KJNtdpy; fhyk; - Mdp> Mb   
thjkhdJ KJNtdpy; gUtj;jpy; jd;dpiy tsh;r;rpAk;> fhHfhyj;jpy; 
Ntw;Wepiy tsh;r;rpAk;> $jph;fhyj;jpy; jd;dpiyAk; milfpd;wJ. 
moyhdJ fhHfhyj;jpy; jd;dpiy tsh;r;rpAk;> $jph;fhyj;jpy; 
Ntw;Wepiy tsh;r;rpAk;> Kd;gdpf;fhyj;jpy; jd;dpiyAk; milfpd;wJ. 
 IakhdJ gpd;gdpf; fhyj;jpy; jd;dpiy tsh;r;rpAk;> ,sNtdpy; 
fhyj;jpy; Ntw;Wepiy tsh;r;rpAk;> KJNtdpy; fhyj;jpy; jd;dpiyAk; 
milfpd;wJ. Kf;Fw;wq;fspd; Ntw;Wepiy tsh;r;rp Neha; Njhw;wj;jpw;F 
fhuzkhfpd;wJ. 
gpzpawp Kiwik: 
 gpzpawp Kiwik vd;gJ cliyg; gpzpj;jyhfpa Nehiaj; 
njhpe;Jnfhs;Sfpw xOf;fk; vdg;gLk;.  ,J %tiffis nfhz;L mwpag;gLk;. 
1. nghwpahw;Njh;jy; 
2. Gydhwpjy; 
3. tpdhjy; 
nghwpahw;Nwh;jy; 
 %f;F  - ,ay;G 
 eh  - ,ay;G 
 fz;  - ,ay;G 
 Njhy;  - ghjpg;gile;J Gz;> jbg;G>ntbg;G> ePHf;frpTld;  
   fhzy; 
 nrtp  - ,ay;G 
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Gydhwpjy; 
 ehw;wk;  - ,ay;G 
 Rit  - ,ay;G 
 xsp  - ,ay;G 
 CW  - ghjpg;gile;J jpkph;> jpdT> nrhwpAld; fhzy; 
 Xir  - ,ay;G 
tpdhjy; 
 gpzpAw;Nwhdplj;J cs;s nghwp> Gyd;fs; gpzpfis 
njspthAzh;j;Jkhifahy;> kUj;Jtd; jd;id Nehf;fp te;j gpzpAw;wtidg; 
gw;wp mwpa Ntz;batw;iw mwpe;Jk;> jd; nghwp> Gyd;fshy; gpzpahsDila 
nghwp> Gyd; topaha; czh;tijf; Nfl;L mwpe;J nfhs;s Ntz;Lk;. 
vz; tifj; Njh;T 
 “ehbg;ghprk; ehepwk; nkhoptpop 
 kyk; %j;jpukpit kUj;JtuhAjk;” 
gpzpawpAk; KiwahdJ kUj;Jt E}y; ty;NyhHfshy; vz; tifaha; 
tFf;fg;gl;Ls;sJ. 
eh 
 eh khrw;W cs;sjh> kh gbe;J cs;sjh mjd; epwk; Mfpatw;iw 
ftdpj;jyhFk;.   
epwk;: 
ghy fug;ghd; gpzpapy; Njhypd; epwkhdJ ghjpg;gile;J rpte;j 
epwkhfNth my;yJ fUik epwkhfNth fhzg;gLfpd;wJ. 
nkhop 
 Nehahsp NgRk; NghJ rk xyp> fgj;NjhL $ba Ngr;R cuj;j Ngr;R 
Mfpaitfis mwpjyhFk;.  ghy fug;ghd; Nuhfj;jpy; nkhop ,ay;ghf 
cs;sJ. 
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tpop 
 fz; ntspwy;> rptj;jy; Nghd;w FwpFzq;fis Muha;tjhFk;.  ghy 
fug;ghdpy; tpop ,ay;ghf cs;sJ. 
kyk; 
 kyj;jpd; jd;ikia mwpjyhFk;.  ghy fug;ghd; gpzpapy; thjkhdJ 
ghjpf;fg;gl;Ls;sjhy; kyf;fl;L fhzg;gLfpd;wJ. 
ePH 
 “te;j ePHf;fhp vil kzk; Eiu vQ;rnyd; 
 iwe;jpaYstit aiwFJ KiwNa” 
 vd;gjd; gb ,opfpd;w ePUf;F 1. epwk; 2. vil 3. ehw;wk;                
4. Eiu 5. vQ;ry; vd Ie;J ,ay;fs; cz;L. 
1. epwk;  : ePhpd; epwj;ij mwpjy; Ntz;Lk;.  ghy fug;ghdpy;  
    ePhpd; epwk; ,skQ;rs;. 
2. kzk;  : ePhpd; kzj;ij mwpjy; Ntz;Lk;. 
3. vil  : ePhpd; vilia mwpjy; Ntz;Lk; 
4. Eiu  : Eiu cs;sjh vd;W mwpjy; Ntz;Lk; 
5. vQ;ry;  : ePH mstpy; Fiwjy; my;yJ kpFjy; ,tw;iw  
    mwpjy; Ntz;Lk;. 
nea;;f;Fwp  
 ePH epwf;Fwpahy; Nehiaf; fz;L gpbj;jw; nghUl;Lr; nrhy;ypapUf;fpd;w 
tpjp nghUe;jpa rpWePhpy; xU rpwpa Jsp vz;nzia eLtpy; ifairtpdhy; 
vz;nza;j; Jsp rpjwhky; tpl;L nta;apyhdJ me;ePhpy; gLk;gb jpwe;J 
fhw;whdJ mjpy; tPrp me;j vz;nza;j; Jsp Mlhjgb itj;J mr;rpWePhpy; 
tplg;gl;bUf;fp;;;d;w vz;nza;j; JspahdJ nry;Yfpd;w topapy; fz;zwpitAk;> 
capuwpitAk; nrYj;jp mj;Jsp njhptpf;Fk; Neha; tpsf;fj;ij mwpjy; 
Ntz;Lk;. 
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ghy fug;ghd; Nuhfj;jpy; nea;f;Fwp 
“muntd ePz;bbw; m/Nj thjk;” 
 vz;nza; Jsp tpl;lgpd; mJ ghk;G Nghd;W ePSkhapd; m/J thj 
Nehapidf; fhl;Lk; nea;f;FwpahFk;. 
 “Mop Nghy;gutpd; m/Nj gpj;jk;” 
 vz;nza; Jsp tpl;lgpd; mJ Nkhjpuk; Nghd;W guTkhapd; m/J gpj;j 
Nehapidf; fhl;Lk; nea;f;FwpahFk 
“Kj;njhj;J epw;fpd; nkhoptnjd; fgNk” 
vz;nza;j; Jsp tpl;lJ tpl;lthNw rpwpJk; guthky; Kj;Jg;Nghy; epd;wJ.  
Ia Nehapidf; fhl;Lk; nea;f;FwpahFk;.   
ehb: 
 “rpwg;ghd thjj;jp Yl;bze; jhNd 
  Nrh;e;jpL fpyjprhu Kisr;ry; thA 
 ciug;ghd nghUknyhL mf;fpdp ke;jk; 
  cs;shFk; ePHr;rpwg;G gpuNkfq;fs; 
 gpwg;ghL kjfhp ePH fug;ghd; uj;jk;.......” 
       - rjf ehb 
 thj ehbahdJ kpFjpaile;J mjDld; c\;zKk; Nrh;e;jhy; fug;ghd; 
Nehapid cz;lhfpd;wJ. 
  “jhdKs;s Nrj;Jke;jhdpsfpy; ntg;G 
   rakPis ,Uky; ke;jhu fhrk; 
  <dKWQ;re;jp tplNjhlk; tpf;fy; 
   ,Uj;Nuhfq; fug;ghd; tpuz Njhlk;....” 
Nrj;Jkk; ehb jd;dstpy; ,Ue;J mjpfhpj;Jf; fhZk; NghJ fug;ghd; Neha; 
cz;lhfpd;wJ. 
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ghprk;: 
 ghy fug;ghd; gpzpapy; ];ghprk; ghjpg;gile;J RuRug;Gld; ePH girapd;wp 
jpkph;> jpdT> nrhwp> Gz;> jbg;G ntbg;G> ePH tbjy;> Njhypy; epwkhw;wk; Mfpa 
FwpFzq;fSld; fhzg;gLfpd;wJ. 
kUj;Jtk;: 
 Neha; Njhd;Wtjw;fhd fhuzq;fisf; fz;lwpe;J mjw;Fhpa rpfpr;ir 
Kiwia gj;jpaj;Jld; filg;gpbj;J> Neha; tuhky; jLg;gjw;Fhpa Kiwiaf; 
ifahStNj rpj;j kUj;Jtj;jpd; rpwg;ghd nfhs;if MFk;.  ,J %d;W 
gphpTfSs; mlq;Fk;. 
1. fhg;G 
2. ePf;fk; 
3. epiwT. 
fhg;G: 
 rpj;j kUj;Jt Kiwapy; fhg;G vd;gJ Kjd;ikahd xd;whFk;.  Neha; 
Njhd;Wtjw;F fhuzkhdtw;iw jLj;J MAis ePbf;fr; nra;tNj fhg;ghFk;.   
ePf;fk;: 
 cliy fhg;gjw;Fhpa newpfis filg;gpbj;J elf;fj; jtWthdhapd; 
tsp> moy;> Ia Fw;wq;fspdhy; cz;lhd Neha;fshy; Jd;gkilthd;. 
mq;qdk; tUtpj;Jf; nfhz;l gpzpfisg; Nghf;Fk; tpjpfNs ePf;fk; vdg;gLk;.  
gpzpahdJ Kf;Fw;wq;fis jd;dpiyf;Ff; nfhz;L tUtjd; %yk; 
ePf;fg;gLfpd;wJ. 
kUj;Jt Kiw:  
  ghyfug;ghd; gpzpapy; ,Wjpapy; gpj;j Fw;w tpfhuKw;W 
Neha;f;FwpFzq;fs; kpFjpg;gLtjhy; mij Kjyhf jd;dpiyailar; 
nra;J gpd; tpfhuKw;w thj> fgf; Fw;wq;fis jd;dpiyg;gLj;Jk; 
kUe;Jfis toq;Fjy; Ntz;Lk;. 
  thjf;Fw;wj;jpdhy; vOe;j kyf;fl;bid rPHnra;a kykpsf;fp 
kUe;Jfis toq;Fjy; Ntz;Lk;. 
  VO clw;fl;LfisAk; td;ikgLj;Jk; kUe;Jfis toq;Fjy;.  
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kUj;Jt mwpTiu 
  Fspg;gjw;F ghrpg;gaW khT> eYq;F khtpid cgNahfg;gLj;j 
Ntz;Lk;. 
 jphpgyh #uzj;jpid FbePuhf;fp Neha;fz;l ,lj;jpid ed;F fotp 
Jilf;f Ntz;Lk;. 
  gj;jpa> mgj;jpa czTg; nghUl;fis mwpe;J czT Kiwia 
Nkw;nfhs;Stjd; %ykhf ghy fug;ghd; gpzpahdJ ePf;fg; gLfpd;wJ 
mgj;jpa czT Kiwfs; 
 mfj;jpAld; G+rzpf;fha; Glyq;fhAk; 
  kd;ghd thiof; fhAz;zhHfs; 
 epfo;j;jpa kPd; fLFld;ntq; fhaq;$l;b 
  epj;jpaNk jpd;dJz;lhy; nebNahdhfhd; 
 nrfj;jpy; epd;w tiuf;fPiu tWf;if khq;fha; 
  jpfl;lhj fj;jhpf;fha; jPdghHf; fha; 
 kfj;Jtkhq; Fk;gKdp aUspr; nra;j 
  khwhj nrhwp gwq;fptsU nkd;Nw. 
mfj;jpf;fPiu> G+rzpf;fha;> Glyq;fha;> thiof;fha;> kPd;> fLF> ntq;fhak;> 
miuf;fPiu> khq;fha;> fj;jhpf;fha; Nghd;wtw;iw cztpy; Nrh;j;Jf;  
nfhs;Sk;NghJ fug;ghd; gpzp kpFjpg;gLtjhy; ,itfis cztpy; ,Ue;J 
ePf;f Ntz;Lk;.  
epiwT: 
 Nehahspia rpj;j kUj;Jt Kiwapy; ghpNrhjpj;J Nehapidg; gw;wpa 
njspthd tpsf;fj;jpidAk;> kUe;Jz;Zk; NghJ filg;gpbf;f Ntz;ba 
tpjpKiwfisAk; nfhz;L Nehapidj; jPhg;gNj epiwthFk;. 
 ghy fug;ghd; gpzpf;F gy E}y;fspy; gw;gy kUe;Jfs; $wg;gl;Ls;sd. 
,Ug;gpDk; Ma;thsh; jdJ Ma;tpw;fhf G+tuRnea;apid Njh;e;njLj;Js;shH.
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3.2 MODERN ASPECT 
SKIN  ANATOMY 
INTRODUCTION 
               The skin is a protective covering  of the body .It provides,Physical, 
Mechanical, Chemical,  and  Immunological protection  from the external 
environment.It has also important  sensory, endocrine, and thermoregulatory  
functions. The human skin shows wide regional variations in structure like  scalp, 
face, ear lobes, back, palm, and soles etc. The skin is a largest organ of the body. The 
skin is the largest organ in the human body.It makes up 16% of total body weight , 
with  a  surface area of 1.8m
2
covering the entire body. The thickness of the skin varies 
from 0.5mm thick on the eyelids to 4.0mm on the heels of human body.  
DEVELOPMENT 
1. The epidermis and its appendages are developed from the ectoderm,about the 
fifth week of the fetal development. 
2. The cornium or true skin is of mesodermal origin. 
3. The substanceous fat appears about the fourth month, and the papillae of the 
true skin about the sixth month. 
4. A considerable desquamation of epidermis mixed with sebaceous secretion, 
constitutes the vernix caseosa by which the skin is smeared during the last 
three months of fetal life. 
5. The nails are formed at the third month and begin to project from the 
epidermis about the sixth month. 
6. Above the fifth month, the fetal hairs appear first on the head and then on the 
other parts. They drop after and given place to the permanent hairs. 
7. The cellular structures of the sudoriferous and sebaceous glands are formed 
from the ectoderm whereas the connective tissue and blood vessels are 
derived from the mesoderm. 
8. All the sweat glands are being to develop as early as the fourth month. 
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9. The skin of an average adult cover an area of just under 2m2.The skin 
thickness ranges from 0.5mm as in the eyelids to 4mm on the heels. Over 
most of the body it is 1-2mm thick. 
 ANATOMY 
                 The skin is composed of a superficial epithelial layer  -the Epidermis, and 
an underlying connective tissue layer-the Dermis or Corium.Beneath the corium is 
another connective tissue layer -the Hypodermis or subcutaneous layer. 
EPIDERMIS 
                 The  matureEpidermis is formed of non-vascular stratified epithelial tissue 
composed of predominantly of keratinocytes . The function of epidermis is protection 
of the organism from the external environment,through physical, chemical, and 
immunologic barrier functions.  Its usual thickness is between 0.07mm and 0.12 
mm.It is thickest on the palms of the hand and soles of the feet.The epidermis is 
mainly divisible into two main systems keratinizing or Malpighian system 
(Keratinocytes) which forms the bulk and the pigmentary system (Melanocytes)  
which produces the  pigment. The epidermis consists of Squamous 
cells(Keratinocytes), Melanocytes(The pigment- forming cells), Langerhans 
cells(Dentritic cells of the mononuclear phagocyte system). 
LAYERS OF EPIDERMIS 
 Stratum germinatum -This is the deepest portion of the epidermis and is 
composed of columnar cells placed perpendicular to the skin surface.The 
whole of the epidermis germinates from this stratum hence the name 
“stratum germinatum”. 
 Stratum malpigii–It is superficial the basal cell layer,and is composed of 
several layers of polyhedral cells connected to each other by intercellular 
bridges. 
 Stratum granulosum-It is superficial to stratum malpigii.It is composed of 
flat, fusiform cells which are one to three layers thick.These cells contain 
irregular granules of Keratohyalin and lysosomal enzymes and cystine rich 
proteins. 
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 Stratum lucidum–It is superficial to the stratum  granulosum . It is pale, 
wavy-looking klayer known as stratum lucidum which is formed by many 
layers of flattened and closely packed cells . 
 Stratum corneum  -This is the most superficial layer ,the outer surface of 
which is exposed to the atmosphere.It is formed by many layers of non 
nucleated,flattened, cornified cells. 
DERMIS 
The dermis forms a tough, pliable,  fibrous supporting structure between the 
epidermis and the subcutaneous fat. The thickness of the skin is 1-3 mm.It is 
profusely supplied with blood vessels. The connective tissue cells in the dermis are 
spindle shaped fibroblast that is responsible for the synthesis of collagen, elastic fibres  
and  mucopolysaccharides. Phagacytic histiocytes, mast cells and motile leukocytes 
are also present. Within the dermis are blood vessels, lymphatics, neural structures 
,eccrine and apocrine sweat glands, hairfollicles, sebaceousglands and smooth muscle. 
Morphologically, the dermis can be divided into two layers, the superficial papillary 
layer that interdigitates with the reteridges of the epidermisand the deeper reticular 
layerthat lies beneath the papillary dermis.  The extracellular matrix of the dermis 
consists of collagen and elastic fibers embedded in an amorphous ground substance. 
Collagen provides strength and stability to the dermis, while elastic fibers allow for  
elasticity. 
SUBCUTANEOUS TISSUE 
The panniculus, or subcutaneous tissue, consists of fat cells and fibrous septa 
that divide it into lobules and anchor it to the underlying fascia  and  periosteum. 
Bloodvessels and nerves are also present in this layer which serves as astorage depot 
for lipid, an insulator to conserve body heat, and a protective cushion against trauma. 
APPENDAGEAL STRUCTURES 
HAIR 
Hair follicles are distributed throughout the skin, except in the palms,soles, 
lips, and glans penis.Individual follicles extend from the surface of the epidermis to 
the deep dermis. The hair follicle is divided into four segments: the infundibulum, 
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which extends from the skin surface to the sebaceous duct; the isthumus extending 
from the sebaceous  duct opening to the bulge; the lower follicle between the bulge 
and the hair bulb;and the hair bulb. The bulge is at the insertion of the arrectorpili 
muscle and is a focus epidermal stem cells.The bulb is where the matrix cells and 
dermal papilla are involved in formation and maintenance of the hair. Each hair 
follicle is lined by germinative cells, which produce keratin and melanocytes,which 
synthesise pigment.The hair shaft consists of  an outer cuticle,a cortex of 
keratinocytes and  an inner medulla. The root sheath which surrounds the hair bulb,is 
composed of an outer and inner layer. Hair growth is under endocrine control. Hair 
grows about 1-2 cm per month. 
ANATOMY OF THE SKIN 
CROSS SECTION  OF THE SKIN 
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SEBACEOUS GLANDS 
                   Sebaceous glands occur in all areas except the palms, soles and dorsal feet 
and are most numerous on the face,upper chest and back.They are situated in upper 
half of the corium. Their ducts open into the hair follicles except on the lips, prepuce, 
and labia minora,where they emerge directly onto the mucosal surface.These 
holocrine glands are saccular structures that  are often branched and lobulated  and 
consist of a proliferative basal layer of  small flat cells peripheral  to the central mass 
of lipidized cells.The latter cells disintegrate as they move toward the duct and form 
the lipid secretion known as sebum,which consists of  triglycerides, wax 
esters,squalene and  cholesterol esters.The purpose of  sebum production likely relates 
to hydrophobic skin carrier  function.Sebaceous glands depend on hormonal 
stimulation and are activated by androgens by puberty. Fetal sebaceous glands are 
stimulated  by maternal androgens and their lipid secretion,together with  
desquamated  stratum corneum cells, constitutes the vernix  caseosa. 
APOCRINE GLANDS 
 The apocrine glands are located in the axillae, areolae, perianal , genital areas 
and  the periumbilical region.These large,coiled, tubular structures continuously 
secrete an odorless milky fluid that is discharged in response to adrenergic stimuli, 
usually  as a result of emotional stress. Bacterial biotransformation of apocrine sweat 
components(fatty acids, thio alcohols and steroids) accounts for the unpleasant odour 
associated with perspiration. Apocrine glands remain dormant until puberty, when 
they enlarge and secretion begins in response to androgenic activity. The secretory 
coil of the gland consists of a single layer of cells enclosed by a layer of  contractile 
myoepithelial  cells. Although apocrine glands, do not function in thermoregulation  
they are involved in certain disease processes. 
ECCRINE SWEAT GLANDS 
Eccrine sweat glands are distributed over the entire body surface and are most 
abundant on the palms and soles.those on the hairy skin respond to thermal stimuli 
and serve to regulate body temperatre by delivering water to the skin surface for 
evaporation;in contrast, sweat glands on the palms and soles, respond mainly to 
psychophysiologic stimuli. 
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                    Each eccrine gland consists of secretory coil located in the reticular 
dermis or subcutaneous fat and a secretory duct that opens onto the skin surface.The 
glands are supplied by sympathetic nerve  fibers, but the pharmacologic mediator of 
sweating is acetylcholine  rather than epinephrine.sweat from these glands consists of 
water, sodium, potassium, calcium, chloride, phosphorus, lactate and small quantities 
of  iron, glucose and protein. The composition  varies with the rate of  sweating but is 
always hypotonic in normal children. 
NAILS 
  Nails are specialized protective epidermal structures that form 
convex,translucent,tight-fitting plates on the distal dorsal surfaces of the fingers and 
toes. The nail plate,which is derived from a metabolically active matrix of multiplying 
cells situated beneath the posterior nail fold,is composed of anucleate 
keratinocytes.Nail growth is relatively slow;complete finger nail regrowth takes 6 
months, while complete toenail regrowth requires 12-18 months.The nail plate is 
bounded by the lateral and posterior nail folds;a thin eponychium(cuticle) protrudes 
from the posterior fold over a crescent-shaped white area called the lunula.The 
eponychium serves as a sealant barrier to protect the germinal matrix of the nail plate. 
Nail health relies on several factors,including nutrition, hydration, local 
infection/irritation and systemic disease. 
BLOOD VESSELS 
The cutaneous arteries arise directly or indirectly from the underlying source 
arteries forming anstomosis in the deepest part  of the cortex.From here single vessels 
run upwards  and form a second network in the upper cortex. Finally teminal 
arterioles ascend into the  papillae ending in capillary loops,which drain into 
connecting venules. The blood is returned to the large veins in the subcutaneous 
tissue. 
LYMPHATICS 
The skin contains a rich a network of lymphatics which drain into a few larger 
vessels in the hypodermis.  
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NERVE SUPLY 
The nerve supply of skin consists of motor sympathetic portion derived  from 
the symphathetic ganglia and sensory spinal portion arising from the dorsal root 
ganglia.The symphathetic fibre innervate the blood vessel, erector pilorum muscles 
and adrenergic and cause contraction. 
FUNCTIONS OF THE SKIN 
Protective function 
The  epidermis and  sub cutaneous fat play roles in the protective functions, 
the mechanical properties of the skin depends mainly on the dermis. It forms an 
effective barrier against microbial invasion and has properties of  mechanical, 
chemical, atomic, thermal and phototic damage. 
Immunological function 
The skin is a dynamic organ that contains different cells which contains 
elements of the innate and adaptive immune system which are activated when the 
tissue is under attack by invading pathogens. 
Sensory function 
The skin is richly supplied with nerves . It has many nerve endings , which 
form the specialized cutaneous receptor which provide information regarding 
environmental changes to the brain. 
Secretion  function 
Skin  secretes sweat through sweat glands and sebum through sebaceous 
glands. By secreting sweat, skin regulates body temperature and water balance. 
Sebum keeps the skin smooth and moist. 
Excretion function 
Skin can excrete small quantities of waste materials like urea, salts and fatty 
substance. 
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Synthesis of vitamin “D” 
                  UV rays act on the skin to form Vit D3, activated in liver and kidneys, 
active form then acts on the intestines to increase calcium and phosphate absorption 
and on bone to increase calcium  and phosphate mobilization. 
 Body heat regulation 
                  Skin  plays an important role in the regulation of body temperature.Excess  
heat is lost from body through skin by radiation, conduction, convection and 
evaporation. Sweat glands of the skin play active part in heat loss  by secreting sweat. 
The lipid content of sebum prevents loss of heat from the body in cold environment.  
 Regulation of water and electrolyte balance 
                Skin  regulates water balance and electrolyte balance by excreting water and 
salts through sweat. 
Storage function of skin 
                  Skin  stores fat,water, chloride and sugar. It can also store blood  by the 
dilatation of the cutaneous blood vessels 
Absorption 
           Skin can absorb the fat soluble substances and some ointments. 
Gaseous exchange through skin. 
                  A small amount of gaseous exchange occurs through the skin , the amount 
of co2 exchanged through the skin is negligible compared to the amount exhaled from 
the lungs. 
Pigment of skin 
                Melanin pigment protects the skin from the harmful effects of ultraviolet 
rays. 
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ATOPIC  DERMATITIS (or)ATOPIC ECZEMA 
                   The signs and symptoms of “ Balakarappan” are closely similar to signs 
and symptoms of Atopic Dermatitis(AD). Atopic dermatitis (AD) or eczema is the 
most common chronic relapsing skin disease seen in infancy and childhood. It affects 
10-30% of the children worldwide and frequently occurs in families with other atopic 
disease such as asthma allergic rhinitis, and food allergy. Infants with Atopic 
dermatitis are predisposed to development of allergic rhinitis and asthma later in 
childhood , a process called “the atopic march”.  
DEFINITION 
    Atopic dermatitis is an inflammatory skin disorder characterized by erythema, 
edema, intense pruritis, exudation, crusting and scaling. 
EPIDEMIOLOGY 
           The prevalence of Atopic dermatitis has increased over the past 30 years. It is 
currently estimated that 10-20% of children and 1-3% of adults in developed countries  
in within are affected by the disorder. Atopic dermatitis often starts in early infancy,  
approximately 45% of all cases begin  within the first 6 months of life  60%  during 
the first year and 85 % before 5 years of age upto 70% of these children outgrow the 
disorder before the adolescence. Children with atopic dermatitis are at high risk of 
developing asthma and allergic rhinitis of those who will develop Atopic dermatitis 
before the age 2, 50% will develop asthma during subsequent years. The prevalence 
of eczema is on the increase and currently affects 12- 15% of all school age children  
 Aetiology 
   Atopic dermatitis is a complex genetic disorder that results in a 
 Defective skin barrier 
 Reduced skin innate immune response 
 Exaggerated T-cell response to environment allergens and microbes that lead 
to chronic skin inflammation. 
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Pathology 
            Acute Atopic dermatitis skin lesions are characterised by spongiosis or marked 
intercellular oedema of the epidermis. Antigen presenting cells (APCs) in the 
epidermis, such as langerhans cells (LCs) exhibit surface bound immunoglobulin (Ig 
E) molecues. 
              These ACPs play an important role in cutaeous allergen presenting to T 
helper type 2 (th 2) cells. There is a marked perivenular T-cells infiltrate with 
occasional monocyte- macrophages in acute Atopic dermatitis lesions. Mast cells are 
found in normal numbers but in different stages of degranulation. 
               Chronic lichenified Atopic dermatitis is characterised  by a hyperplasic 
epidermis with hyperkeratosis, and minimal spongiosis. There are predominantly IgE- 
bearing LCs in the epidermis,and macrophages in the dermis. Mast cell and eosinophil 
numbers are increased. Eosinophil contribute to allergic inflammation by secreting 
cytokines and mediators that augment inflammatory responses and induce tissue 
injury in Atopic dermatitis through the production of reactive oxygen intermediates 
and release of toxic granule proteins. 
Pathogenesis 
              Two forms of Atopic dermatitis have been identified 
1) Atopic eczema is associated with IgE mediated sensitization and occurs in 
70-80% of patients with Atopic dermatitis 
2) Non atopic dermatitis is not associated with IgE mediated sensitization and is 
seen in 20-30% of patients with Atopic dermatitis. Both forms of Atopic 
dermatitis are associated with eosinophilia. 
       In atopic eczema circulating T cells expressing the skin homing receptor 
cutaneous lymphocyte – associated antigen (CLA) produced increased levels of th2 
cytokines,interleukin (IL-4) and another cytokine IL-5 Plays an important role in 
eosinophil development. 
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        Non atopic eczema is associated with lower IL-4 and IL-3 production than is 
atopic eczema. The developement of AD skin lesion is orchestrated by local tissue 
expression of pro inflammatory cytokines and chemokines. Cytokines such as tumour 
necrosis factor  𝛼 (TNF - 𝛼) and IL -1 from keratinocytes, mast cells and dendritic 
cells bind the receptor on vasular endothelium. 
          These events proceed from tethering activation and adhesion to the 
endothelium, followed by extravasation of inflammatory cells. Once the inflammatory 
cells infiltrate the tissue, they respond to chemo tactic gradients established by 
chemokines,released at sites of injury or infection.Chemokines plays  a central role in 
defining the nature of the inflammatory infiltrate in Atopic dermatitis. Other c-c 
chemokines,monocytes, chemo tactic protein -4 (MCP -4) exotaxin,macrophage- 
derived chemokines (MDC) are increased in Atopic dermatitis. Elevated IL-5 and 
GM/CSF of eosinophils and monocyte – macrophages as well as LCs. 
               In healthy people the skin acts as a protective barrier against external 
irritants, moisture loss and infection. Proper function of the skin depends on adequate 
moisture and lipid content, functional immune responses and structural integrity. 
Several dry skin is a hallmark of atpoic dermatitis. 
                This is a result of compromise of physical and chemical structures of the 
epidermal barrier,which leads to excess transepidermal water loss. Filaggrin a 
component of the cytoskeleton and its breakdown products are critical to skin barrier 
function. Genetic mutations in the filaggrin gene family have been identified in up to 
50% severe patients with Atopic dermatitis. Such patients have increased risk of 
bacterial, viral and fungal infection rrelated to impairment of innate immunity, 
including a loss of barrier and impaired generation of antimicrobial peptides. 
Potential Atopic dermatitis triggers: 
Associated with food: 
 Food allergens found in cow‟s milk,eggs, peanuts 
 Tree nuts (eg, walnuts,cashews) Soy, wheat,fish,shelfish 
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Associated with direct contact 
 Toiletries contacting alcohol,astringents, or fragrances harsh detergents\ 
soaps  
 Abrasive clothing (wool or synthetics) 
Associated with physiologic /emotional stressor 
 Infections (Especially from overheating/sweating) 
 Psychological stress 
 Other factors   
 Irritants     - physical , chemical or electrical 
 Sensitizers  - plants , clothings,cosmetics,infections , diet, and focal sepsis 
 External infections – streptococci, staphylococci, fungus.. 
 Internal septic focus shedding toxins or causing bacteraemia. 
 Diathesis  - Allergic, xerodermic, hyperhidrotic or seborrhoeic 
 Drugs -     given for the diseaes or otherwise 
 State of local or general nutrition 
 Climate -    Temperature and humidity 
Clinical manifestations 
 Atopic dermatitis typically begins in infancy 50% of patients experience   
symptoms in the 1 st yr of life & additional 30%  all diagnosed between 1-5 yr of age. 
Cardinal features of Atopic dermatitis are 
In acute stage 
Intense pruritic with erythematic papular lesions. 
In subacute stage 
            Erythematous Excoriated, scaling papular lesion. 
 
35 
 
In chronic stage 
Lichenification or thickening of skin with accentuated surface markings and 
fibrotic papular ( prurigo nodularis ). In chronic Atopic dermatitis all three types of 
reactions may coexist in same individual. 
Acute Atopic dermatitis in infants 
 Extensor surface of extremities ,face (forehead, cheeks) 
 Neck ,scalp,trunk 
Chronic Atopic dermatitis in childhood ( 2 years to puberty ) 
 Flexual surface of extermities 
 Neck ,wrist, ankles 
Clinical Features of Atopic dermatitis 
Major features 
 Pruritis , personal or family history of Atopic dermatitis 
 Facial and extensor eczema in infants and children. 
 Chronic or relapsing dermatitis 
Associated Features 
 Xerosis, keratosis ,ichthyosis,palmar hyper linearity 
 Cutaneous infections(staphylococcus,herpes simplex, moliuscum warts) 
 Non specific dermatitis of the hands or feet 
 White dermagraphism , Early age at onset 
 Elevated serum Ig E levels, Facial erythema or pallor 
 Positive results of immediate type allergy skin test 
 Course influenced by environment \emotional factors 
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Lab Findings 
 No specific Laboratory tests to diagnose Atopic dermatitis 
 Peripheral blood eosinophilia 
 Increased serum Ig E levels 
 Prick skin test to identify the allergen. 
Differential Diagnosis of Atopic Dermatitis 
Infections and infestations 
 Scabies, Dermatophytosis 
 HIV associated dermatitis,Insect bites. 
Congenital Disorders 
 Familial keratosis pilaris 
 Netherton syndrome 
Chronic dermatomes 
 Seborrhoea dermatitis, contact dermatitis 
 Nummular dermatitis 
 Psoriasis dermatitis, ichthyosis dermatitis 
Auto immune disorder 
 Dermatitis herpetiformis 
 Pemphigus foliaccus, Hyper Ig E syndrome 
Metabolic disorder 
 Zinc deficiency, Pyridoxin niacin, Phenyl ketonuria 
Treatment 
          The Treatment of Atopic deramtitis requires a systematic multifaceted approach 
that incorporates – Skin hydration 
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                         Topical anti inflammatory therapy 
                          Identification and elimination of flare factors 
                          Systemic therapy. 
Categorization  of physical severity of Atopic dermatitis 
       Clear          - Normal skin with no evidence of Atopic dermatitis 
       Mild           - Area of dry skin , infrequent itching (with or without redness) 
       Moderate    -Area of dry skin ,infrequent itching redness 9with or without 
excoriation and localised skin thickening) 
       Severe        - Widespread area of dry skin ,incessant itching,Redness (with or 
without excoriation,extensive skin thickening , bleeding, oozing, cracking and 
alteration of pigmentation) 
Life style changes and general  treatments for Atopic dermatitis 
 Avoiding hot tubs, steam baths and chlorinated swimming pools 
 Avoiding scratchy clothes, getting skin patch test 
 Minimizing skin dryness by using lotion specifically designed for sensitive 
skin, drinking plenty of fluids 
 Preventing flare- ups by avoiding exposure to the specific allergen or 
allergens that induce the condition 
 Using ice bags or cool wet compresses to help relieve itching and 
inflammation, using mild soaps and not over harshly scrubbing skin. 
Prick Test 
          Prick test are a way of detectimg cutaneous typr I (immediate) hypersensitivity 
to varius antigens such as pollen, house dust ,mite or dander. 
Patch Test 
 Patch test detect type IV ( delayed or cell- mediated ) hypersensitivity 
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  It is common practice for a battery of around 20 common antigens, including 
common sensitizers such as nickel,rubber and fragrance mix to be applied to the skin 
of the back under aluminium discs for 48 hours. The sites are then examined for a 
positive reaction 24 hours later and again a further 2 hours  later. The positive test is 
revealed by the development of an eczematous patch  with erythematic swelling and 
vesicles at the site of application. 
Patch Test reaction is graded in the following degrees 
        +            - Only redness 
        ++          - Marked redness and swelling 
        +++        - Marked redness , swelling and papules 
        ++++      - Redness, oedema and vesicles 
Specific Ig E levels to antigens can be measured in serum by a specific radio 
allergic sorbent test (RAST). These are occasionally performed to support diagnosis 
of Atopic eczema and to determine specific environment allergens,eg. Pet dander , 
horse hair,house dust mite , pollens and foods. 
Bacterial and viral swabs for microscopy and culture 
         These are useful tests in suspected secondary infection. Skin swabs for 
bacteriology assessment will invariably reveal the presence of bacteria. In the case of 
recurrent impetigo in a child  with atopic eczema , bacterial swabs should be taken 
from carrier sites (axillae and groin) from both the affected individual and house hold 
members. 
Prognosis of Atopic dermatitis 
         Dermatitis and Eczema are as rule curable conditions. Dermatitis is mostly non-
infective and they donot leave scars. The patient needs reassurance of these points. It 
must be remembered that epidermis is an ectodermic structure and so takes time to 
heal. 
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        Acute eczema heals readly in about 1-4 weeks with treatment. Chronic eczemas 
in which anatomical and fuctional changes set in, take time to disappear. 
Disseminated and generalised eczemas are not only slow to heat, but are 
accompanined by ill health. 
        Infantile and Atopic eczema are troublesome and uncomfortable.The former lates 
till the age of twenty five or even though life. Its course is marked by spontaneous 
remissions and exacerbations. Psychogenic stresses, climate extremes and poor health 
aggravate eczema. The cure of these conditions is restarted in tropical countries by 
heat, humidity and the prevalent unhygienic condition.  
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3.3  TRIAL DRUG 
 
 
 
 
 
 
 
                                                  POOVARASU NEI 
                                      INGREDIENTS OF TRIAL MEDICINE 
 
 
   
 
 
                            Poovarasam Pattai                 Poovarasam Pattai Saaru 
 
 
 
 
 
  Kasakasa                        Kasakasa Paal              Sittrimanaku Ennai  
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Nuna Ver                                Sadamanjil                       Manjal Karisalai      
 
                 
 
 
 
 
 
            Elarici                              Karunjeeragam                     Seeragam  
 
 
 
 
 
 
 
 
             Kirambu                              Karpogarisi           Sarkarai  
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PREPARATION AND PROPERTIES OF TRIAL DRUGS 
G+tuR nea; 
       ,ak;gNt ,e;Neha;f;F nea;jh ndhd;W 
,d;gkha;r; nrhy;YNthk; ed;wha;f; Nfsha; 
       ,ak;gNt G+turk; gl;ilr; rhWk; 
,d;gKld; jhNdNahh; gbA nka;aha;; 
       ,ak;gNt rpw;Nwuz; nlz;nza; xd;W 
,ay;ghf ,t;tpuz;LQ; Nrh;j;nj hpj;jq; 
       fpak;gNt frfrhg;ghy; gbjh ndhd;whk; 
              ,UrPu fj;jpndil fhh;Nfhy; fhNy. 
 
       fhyhd VyKld; ytq;f khQ;rpy; 
              fhprhiy EzhNtUk; tifg;g ye;jhd; 
       ePyhd epoYyh;j;jpr; #u zQ;nra; 
neLQ;rPdp gyike;J epWj;njhd; whf;fp 
       thyhd rhnwz;nz aLg;gp Nyw;wp 
tifAlNd fLjpuz;lhy; #uzk;Nghl; 
       Nlyhd fpz;bnea;g; ghf khf;fp 
,wf;fpae;j nea;ajid tbj;Jf; nfhs;Ns 
       tbj;JNk fuz;bepiw  As;Sf; Nfw;w 
thyfug; ghd;Nuhfk; tifnfl; NlhLk; . 
                -Foe;ij kUj;Jtk; g .vz;:398&399 
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METHOD OF PREPARATION 
Internal Medicine : Poovarasu  Nei 
Ref : Kuzhanthai maruthuvam ((Bala vagadam )    Pg no:397,398 . 
Author :DR.G.S.MURUGESA MUDALIAR , DR.PON. GURU SIRONMANI. 
Source of raw drugs: 
                 The Poovarasam pattai and Nuna ver  is collected from my native place, 
Tiruvarur and other required raw drug is procured from a well reputed indigenous 
drug shop from Paris town,Chennai .All raw drugs  were  authenticated by the 
Pharmacognosist, SCRI Chennai.    
Purification of raw drugs: 
              Raw drugs are purified as mentioned in Sikicharathna deepam Sarakku 
Suthi Muraigal. 
INGREDIENTS 
 1.Poovarasam pattai Saaru(Thespesia populnea)                   -1.3 liters             
2.Sittramanaku ennai(Ricinus communis)                               -1.3 liters 
3.Kasakasa paal(Papaver Somniferum)                                  -1.3 liters                         
4.Seeragam(cuminum cyminum) 
5.Karunjeeragam(Nigella sativa)                                             -10gms  
6.Karpogarisi(psoralea carylifolia) 
7.Nuna ver(Morinda tinctoria)  
8.Elarici(Elettaria cardamomum) 
9.Sadamanjil(Nardostachys grandiflora)                               -  40gms 
10.Manjal Karisalai Samulam (widelia calendulaceae) 
11.Kirambu(syzygium ar omaticum) 
12.Sarkarai(Saccharum officinarum)                                    - 200gms 
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PREPARATION 
         All the drugs were purified.Milk of kasakasa  and  the juice of poovarasampattai 
was taken.Both are mixed with castor oil. All other Ingredients are made into fine 
powder. Boil the mixture of castor oil  until the kaduku thiral padham occurs and then 
add the powdered drugs to the above oil till it becomes nei form and filter it. 
DRUG STORAGE: 
        The trial drug is stored in clean air tight container  and it is dispensed to the 
patients  
DOSE:  4ml ( 3-7yrs) , once a day  (morning) 
DURATION: 28days 
PROPERTIES OF TRIAL DRUG 
1.G+turk; gl;il 
 Botanical name: Thespesia populnea 
English name      :Heart wood 
Family                 :Malvaceae 
Organoleptic character 
Suvai                    : kaippu 
Thanmai              :Veppam 
Pirivu                   :kaarppu 
G+turk; gl;il 
 E}w;whz;L nrd;wnjhU E}z;G+ turk;Nth; 
 J}whz;l Fl;ilj; njhiyf;Fq;fhz; - tPwpg; 
 gOj;j,iy tpijG+g;gl;ilapit fz;lhw; 
 GOj;jGz;tp NurdKk; Nghk; . 
 Fl;lq; fb#iy nfhy;Yk; tplghfj; 
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 Jl;l kNfhjuKQ; NrhignahL – fpl;bnkapy; 
 jhTfug; ghd;fpue;jp jz;Nkfk; Nghf;fptpLk; 
 g+turq; fha;g;gl;ilg; G+. 
                           -mfj;jpah; Fzthflk; 
Chemical constituents: 
            Thespone,thespesone,  mansonone-D,mansonone-E, mansonone- F, 
mansonone- G,gossypol, oleic acid, quercetin, thespesin . 
Actions: 
         Anthelmintic, Depurative,Hepatoprotective,Astringent,Antioxidant 
Pharmacological activities:  
        Anti bacterial, Immuno modulator, Anti oxidant,  
2.Ezh Nth; 
Botanical name: Morinda tinctoria 
English name      :IndianMulberry 
Family                 :Rubiaceae 
Organoleptic character 
Suvai                    : kaarppu 
Thanmai              : Veppam 
Pirivu                   : kaarppu 
Ezh 
  gl;il fug;gndhL ghur;rp Ny\;kRuk; 
  xl;bepd;w Gz;fpue;jp Xl;Lq;fhz; - kl;lyiu 
  Ve;J Ezhtpd; ,iyke;jk; jPh;j;Jey;y 
  fhe;jpjU NkfkLq; fhz;.               
  -mfj;jpah; Fzthflk; 
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Chemical constituents: 
 Morindone,rubiadin,carotene, vitamin A,linoleic acid, alizarin, amino acids,L-
asperuloside, caproic acid, caprylic acid, rutin . 
Actions:  
 Cathartic 
Pharmacological activities: 
 Anti inflammatory, Anti microbial, Anti bacterial 
3.frfrh 
Botanical name: Papaver Somniferum 
English name      :Opium poppy 
Family                 :Papaveraceae 
Organoleptic character 
Suvai                    :Inippu 
Thanmai              :Veppam 
Pirivu                   : Inippu 
                frfrh 
fpUkp eikr;ry; fpuhzpajp rhuQ; 
rpuePh; mepj;jpiuNghQ; nrg;gpy; - cUtoFq; 
fhe;jpAKz; lhFq; frfrh tpd;Fzj;ijj; 
Njh;e;jth;f;F tpe;JTkhe;  Njh;. 
                       -mfj;jpah; Fzthflk; 
 
Chemical constituents: 
 papaverine, isocorypalmine, laudanine, magnoflorine, methylocodine, 
narcotine, meconine, morphine, codeine, thebaine, pseudomorphine, linoleic acid, 
oleic acid, linolenic acid . 
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Actions: 
 Demulcent,Nutritive,Astringent, Antispasmodic, Aphrodisiac, Sedative, 
Narcotic 
Pharmacological activities: 
 Analgesic, Anti oxidant, Anti diarrheal, Anti spasmodic, Anti cancer, Anti 
bacterial 
4.Mkzf;F vz;nza; 
Botanical name:Ricinus communis 
English name      :Castor 
Family                 :Euphorbiaceae 
Organoleptic character 
Suvai                    : Kaippu 
Thanmai              :Veppam 
Pirivu                   :Kaarppu 
Mkzf;F vz;nza ; 
Mkzf; nfz;nza; jd;id azpepy kwpaf; Nfz;kpd; 
G+kzr; re;JNjhWk; nghUe;jpa thjk; Nghf;Fk; 
jPke;je; jhDk; Nghf;Fe; jpfo;Tld; tpiuT Kz;lhk; 
jPkdf; Flypy; thjQ; Nrh;Fl Nyw;wk;  NghNk. 
     -mfj;jpah; Fzthflk; 
Chemical constituents: 
        Glycerides, ricinoleic, isoricinoleic, stearic, dihydrocystearic acids, lipases, 
alkaloid ricinine  
Actions: 
        Laxative  
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Pharmacological activities: 
         Laxative,Stimulant. 
5.ew;rPufk; 
Botanical name: cuminum cyminum 
English name      :Cumin seed 
Family                 :Umbelliferae(Apiaceae) 
Organoleptic character 
Suvai                    : Kaarppu, Inippu 
Thanmai              :Thatppam 
Pirivu                   :Inippu 
ew;rPufk; 
gpj;jnkD ke;jphpiag; gpd;dg; gLj;jpatd; 
rj;Juit Ae;Jwe;J rhjpj;J – kj;jndDk; 
uhridA kPntd;W ez;igg; gyg;gLj;jp 
NghrdF lhhpnrAk; Nghh; .  
                   -Njud; ntz;gh 
Chemical constituents: 
 Alpha-pinene, two sesquiterpenoid glucosides, cuminoside A and B 
Actions: 
                 Carminative, Stimulant,Stomachic, Anti spasmodic, Diuretic . 
Pharmacological activities: 
          Anti microbial, Anti oxidant, Anti inflammatory,Immunological activity 
6.fUQ;rPufk; 
Botanical name: Nigella sativa 
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English name      :Black cumin 
Family                 :Ranunculaceae 
Organoleptic character 
Suvai                    : Kaippu 
Thanmai              :Veppam 
Pirivu                   :Kaarppu 
fUQ;rPufk; 
fUQ;rP  ufj;;jhd; fug;ghndhL Gz;Zk; 
tUQ;rpuha;g; gPerK khw;Wk; - mUe;jpdhy; 
fha;r;ry; jiytypAq; fz;typAk; NghKyfpy; 
tha;r;r kUe;njdNt it.  
    -mfj;jpah; Fzthflk; 
Chemical constituents: 
           Cymene, carvone, d-limonene, nigellone, melanthin, melanthigenin, 
nigellidine-indazole, campesterol, citronellyl  acetate.The seed contain a fattyoil  rich 
in unsaturated fatty acids like linoleic acid, oleic acid, palmitic acid and stearic acid .  
Actions: 
Carminative, Stomachic, Anthelmintic, Diuretic. 
Pharmacological activities: 
              Anti microbial, Analgesic, Anti  inflammatory, Anti oxidant, 
Immunomodulatory . 
7.fhh;Nghfhprp 
Botanical name: psoralea carylifolia  
English name   :Babchi seed 
Family                 :Fabaceae 
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Organoleptic character 
Suvai                    : Kaippu 
Thanmai              :Veppam 
Pirivu                   :Kaarppu 
fhh;Nghfhprp 
 fhh;Nghf khkhprp fz;lhw; fug;ghd;Gz; 
 gPh;rFt eQ;rpitNghk; gpj;jKz;lhk; - ghh;kPjpy; 
 thj fgeikr;ry; td;nrhwprp uq;FkWQ; 
 rPj kyh;f;Foyha; nrg;G. 
                           -mfj;jpah; Fzthflk; 
Chemical constituents: 
 Corlifolinin,corylifolin, Limonene, Isonerbavachalcone, Psorlidin-2‟,3‟-oxide 
diacetateisoflavone, corylinin, along with six known compounds  isopsoralen, 
psoralen, sophoracoumestan A, neobavaisoflavone, psoralin, uracil . 
Actions: 
         Vasodilator activity, Laxative, Stomachic, Anthelmintic, Diuretic, 
Aphrodisiac,Deobstruent. 
Pharmacological activities: 
 Anti Bacterial, Anti inflammatory,Anti microbial  
8.Vyhprp 
Botanical name: Elettaria cardamomum 
English name      :Cardamom 
Family                 :Zingiberaceae 
Organoleptic character 
Suvai                    : Kaarppu 
Thanmai              :Veppam 
Pirivu                   :Kaarppu 
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Vyhprp 
     njhz;il tha;fTs; jhYF jq;fspy; 
           Njhd;Wk; Nehajp rhuk;gd; Nkfj;jhy; 
    cz;il Nghy;vOq; fl;b fphpr;ruk; 
           coiy the;jp rpye;jp tp\Q;Ruk; 
    gz;il ntf;if tpjhf Neha; fhrKk; 
           ghOQ; Nrhkg;; gpzptpe;J el;lKk;  
    mz;il aPistd; gpj;jk; ,itf;nfy;yhk; 
           My khq;fko; Vy kUe;jNj.                                      
                              -Njud;   Fzthflk; 
Chemical constituents: 
 Myrcene, limonene, menthone, 𝛼- pinene, sabinene, 1,8 – cineol,geraniol, 𝛼 - 
terpinyl acetate, 𝛼 - terpineol. 
Actions: 
 Carminative, Diuretic, Stimulant.  
Pharmacological activities: 
 Anti microbial,Anti  inflammatory,Anti spasmodic. 
9.rlhkhQ;rpy; 
Botanical name: Nardostachys grandiflora 
English name      :Musk root 
Family                 :Valerianaceae 
Organoleptic character 
Suvai                    : Kaarppu 
Thanmai              :Veppam 
Pirivu                   :Kaarppu 
rlhkhQ;rpy; 
Fl;lQ; rpye;jptplk; Nfhu Guhz Ruk; 
cl;bzq;fhy; Ngjpfz;Nzha; xl;bUky; - nrhl;buj;j 
gpj;jkpiug; NgFk; ngUq;Nfhiu vd;Wiuf;FQ; 
Rj;jrlh khQ;rpiy nrhy;.                  
                      -mfj;jpah; Fzthflk; 
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Chemical constituents: 
             Jatamansic acid, jatamansone or valeranone,jatamansinol, jatamansinone, 
nardosinone,seselin,valeranal,oroselone,oroseolol. 
Actions: 
 Stimulant, Anti spasmodic, Diuretic, Expectorant. 
Pharmacological activities: 
 Anti depressant, Anti oxidant, Anti convulsant, Anti fungal. 
10.kQ;rs; fhprhiy 
Botanical name: Wedelia calendulaceae 
English name      :chinese wedelia 
Family                 :Asteraceae(Compositae) 
Organoleptic character 
Suvai                    : Kaippu 
Thanmai              :Veppam 
Pirivu                   :Kaarppu 
kQ;rs; fhprhiy 
    Fuw;fk;kw; fhkhiy Fl;lnkhL  Nrhig 
    Aaw;ghz;L gd;Ndh nahopa – epuw;nrhd;d  
    nka;ahe; jfiunahj;j kPsp z;Z ew;Gyj;Jf; 
    ifahe; jfiunahj;jf; fhy;. 
                             -mfj;jpah; Fzthflk; 
Chemical constituents:  
 Wedelolactone,dimethylwedelolactone . 
Actions: 
Hepato protective,Tonic, Alterative. 
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Pharmacological activities: 
 Anti Bacterial, Anti inflammatory, Analgesic, Anti oxidant, Anti convulsant, 
Sedative, Immunomodulatory, Wound healing,Anti ulcerogenic,Anti helmintic . 
11.fpuhk;G 
Botanical name: syzygium aromaticum 
English name      :Cloves 
 Family                 : Myrtaceae 
Organoleptic character 
Suvai                    : kaarppu, Viruviruppu 
Thanmai              :Veppam 
Pirivu                   :Kaarppu. 
fpuhk;G 
gpj;j kaf;fk; NgjpnahL the;jpAk;Nghk; 
Rj;jtpuj; jf;fLg;Ge; Njhd;WNkh – nkj;j 
,ytq;fq; nfhz;ltUf; Nfw; RfkhFk; 
kykq;Nf fl;Lnkd tho;j;J. 
Chemical constituents: 
Syzyginins A and B, Eugeniin, Ellagitannins, polyoxygenated chromone C- 
glucoside, isobiflorin, biflorin, acetyleugenol, chavicol, acetyl salicylate and 
humulenes,flavonoids,apigenin trioside . 
Actions: 
 Anti fungal, Anti carcinogenic, Anti convulsant, Diuretic, Stomachic, cardiac 
tonic, Carminative, Stimulant, Odontalgic. 
Pharmacological activities: 
             Anti microbial, Anti viral, Anti inflammatory, Anaesthetic, Anti pyretic. 
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12.rh;f;fiu 
Botanical name: Saccharum officinarum 
English name      :Sugar 
Family                 :Poaceae(Graminae) 
Organoleptic character 
Suvai                    : Inippu 
Thanmai              :Seetham 
Pirivu                   :Inippu 
rh;f;fiu 
  rPdpr; rh;f;fiuf;Fj; jPuhj td;RuKq; 
  $dpf;Fk; thjj;jpd; $l;LwTk; - Vdpw;Fk; 
  the;jp nahLfpUkp khwhj tpf;fYNk 
  Nghe;jpiria  tpl;Lg;  Guz;L. 
-mfj;jpah; Fzthflk; 
Chemical constituents: 
 Ligan,Altissinone,Flavonoid, 2”-0-p hydroxybenzolylorietin,Acytylated 
flavone C glucoside . 
Actions: 
 Anti septic, Demulcent. 
Pharmacological activities: 
 Anti oxidant, Anti -microbial  
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MATERIALS AND METHODS 
Study Design 
An open clinical trial of Bala karappan was carried out in the post graduate 
department of    Kuzhanthai Maruthuvam  in Govt siddha mdical college attached to 
Arignar Anna Govt Hospitalof Indian medicine,Chennai -106 during the period of 
2015-2017.. 
  The study was approved on Institutional ethics committee (IEC) and the 
approval number is GSMC-CH-ME-4/017/2015 
Study size  
 The study was conducted in 40 selected patients of both genders of between 
age groups of 3 to7 years. 
Selection criteria 
 The patients having any 4 of the following parameters are selected for the 
study 
 Age:3-7 yrs 
 Itching 
 Erythema 
 Weeping 
 Vesicles 
 Oozing  
 Lichenification 
Exclusion criteria; 
 Scabies 
 Photodermatitis 
 Secondary bacterial infection 
56 
 
Withdrawal criteria: 
 Exacerbations of symptoms 
 Intolerance to the drug and  development of adverse reactions during the trial 
drug .  
 Patients turned unwilling to continue in the course of clinical trial. 
 Any other acute illness 
Tests and Assessments: 
A. Clinical Assessment 
B. Siddha Assessment 
C. Laboratory Investigations 
Clinical Assessment: 
 Itching 
 Papules 
 Vesicles 
 Scaling 
 Oozing 
 Hyperpigmentation 
Siddha Assessment: 
 Naa 
 Niram 
 Mozhi 
 Vizhi 
 Sparisam 
 Malam 
 Naadi 
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 Moothiram-neer kuri,nei kuri. 
Laboratory Investigations 
Blood 
TC,DC,ESR,HB 
Urine: 
Albumin,Sugar,Deposit 
Methodology of treatment 
Study enrolment: 
             Patient‟s parent or guardian reporting at the OPD with child associated with 
clinical features of severe itching,erythema,vesicles,papules,oozing and 
lichenification are chosen for enrolment based on the inclusion criteria. The patients 
who are enrolled are informed about the study of trial drug Poovarasu nei(Internal) 
,possible outcomes and the objectives of the study in their own language and terms 
understandable to them and the informed consentwould be obtained from the patient‟s 
parent or guardian using consent form. 
Conduct of the study 
          On the first day onwards the trial drug “Poovarasu Nei ( Internal)” will be 
given. The trial drug will be given in the OPD department of kuzhanthai 
maruthuvam,GSMC,chennai. The patients will be asked to have a regular follow up in 
the OP department once in 5 days. In each and every visit the clinical assessment will 
be recorded in the prescribed proforma. The laboratory investigationwill be done 
before and after treatment and recorded in the  prescribed format . 
Data collection forms 
Required information will be collected from each patient by using following 
foms. 
Form I                : screening and selection proforma 
Form II              : History taking proforma 
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Form III             : clinical assessment proforma 
Form IV             :Laboratory  investigation proforma   
FormV               : Informed consent form 
Form VI             : Withdrawal form 
FormnVII           : Patient information sheet 
Form VIII           : Informed Assent form 
Form IX              : Diet sheet 
Data Analysis: 
            After enrolling the patients in the study a separate file for each patient is 
maintained  and all  forms are kept in the file. Whenever the patient visits OPD during 
the study period necessary entries will be made in the assessment forms. 
The data entries and adverse events if any will be monitored by the Head of 
the Department. 
Outcome of Treatment 
Primary Outcome 
Primary outcome is mainly assessed by reduction in clinical symptoms 
Secondary Outcome 
Safety of the patients is assessed as a secondary outcome through LFT/RFT . 
Adverse effect and serious effect management 
    If the trial patient develops any adverse reactions the patient will be referred to the 
pharmacovigilence department of SCRI and documented. For any adverse effect the 
investigator will give the proper management in the OPD. 
Ethical issues 
1. Informed Consent/Assent will be obtained from the patient/ patients parent 
or guardian after explaining about the clinical trial in their language. 
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2 . After the Consent/Assent of te patient or patients parent (through 
consent/Assent form)if  they fit in the  criteria they will be enrolled in the 
study. 
3.   Treatment will be provided free of cost. 
4.  Concomitant medicines will be used if there is any need. 
5 .  The patients who are excluded (as per the exclusion criteria) will be referred 
to OPD 
        6.  In conditions of treatment failure, adverse reaction patients will be given 
 rescue medication.  
        Analysis of Trial medicine: 
1. The acute and subacute toxicity study was carried out in Sathyabama 
University, Rajiv Gandhi Salai,Chennai. 
2. The Pharmacological analysis of trial drug for its Antihistamine  and 
Immunological activity was carried out in Sathyabama University, Rajiv 
Gandhi Salai ,Chennai. 
            3. The Bio chemical , Physicochemical  and Phytochemical  analysis was  
 performed in GSMC, Biochemistry laboratory, Arumbakkam, Chennai and in 
 Sathyabama   University, Rajiv Gandhi Salai, Chennai .  
4. Observation made from patients with sign and symptoms of the disease and 
their prognosis were recorded. 
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RESULTS AND OBSERVATION 
A total number of 40 child patients with signs and symptoms of Bala 
karappan attending PG-IV, KuzhanthaiMaruthuvam Out Patient Department in Govt. 
Siddha Medical College attached to Aringnar Anna Hospital were observed in the 
present study. The observations were made and tabulated with regards to the 
following features:  
1. Age Distribution 
2. Gender Distribution 
3. Socio-Economic status 
4. Aetiological factor 
5. Dietary habits 
6. Seasonal reference 
7. Reference to Thinai 
8. UyirThathukkal 
9. Udarthathukkal 
10. Envagaithervugal 
11. Neikkuri 
12. Clinical prognosis 
13. Results after treatment 
The observation recorded are given below in tabular form 
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AGE DISTRIBUTION 
 
S.NO.  AGE   
NO. OF 
CASES  
PERCENTAGE 
1 3-5 yrs 21 52.5% 
2 6-7 yrs 19 47.5% 
 
 
 
Inference  
The above table indicates that children coming under 3-5 years of age group 
were 21(52.5%), 6-7 years were 19(47.5%)  respectively. 
45.00%
46.00%
47.00%
48.00%
49.00%
50.00%
51.00%
52.00%
53.00%
3-5 yrs 6-7 yrs
AGE DISTRIBUTION
52.5%
47.5 %
YEARS
62 
 
SEX DISTRIBUTION 
 
S.NO. SEX 
NO. OF 
CASES 
PERCENTAGE 
1 
Male 
child 
25 62.5% 
2 
Female 
child 
15 37.5% 
 
 
 
 
Inference 
 Among the 40 cases for this present study, 15(37.5%) children were female  
and 25(62.5%) children were male. According to modern theory there is no apparent 
sex prediction. 
 
 
Male child
63%
Female child
38%
SEX  DISTRIBUTION
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SOCIO ECONOMIC STATUS 
 
S.NO. STATUS 
NO. OF 
CASES 
PERCENTAGE 
1 Rich 2 5% 
2 Middle 14 35% 
3 Poor 24 60% 
 
 
 
Inference 
Regarding socio-economic status, 24(60%) cases were belong to poor status, 
14(35%) cases were belong to middle class and 2(5%) cases belong to high class. 
 
 
 
5%
35%
60%
SOCIO ECONOMIC STATUS
Rich Middle Poor 
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FAMILY HISTORY 
 
S.No Family History No. Of Cases Percentage 
1. Positive 16 40% 
2. Negative 24 60% 
 
 
 
 
 
Inference: 
Among the 40 patients, 24(60%) of the patients showed negative family 
history, 16(40%) patients showed positive family history . 
 
 
 
40%
60%
FAMILY HIST0RY
POSITIVE NEGATIVE
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DIETARY HABITS: 
 
S.NO Diet No. of cases Percentage 
1. Vegetarian 4 10% 
2 Mixed 36 90% 
 
 
 
 
Inference: 
90% belonged to mixed diet and 10% belonged to vegetarian diet habit. 
 
 
 
 
 
Vegetarian Mixed
10%
90%
DIETARY HABIT
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SEASONAL REFERENCE 
S.NO. KAALANGAL  NO.OF CASES PERCENTAGE 
1 Kaar(Aavani, purattasi) 3 7.5% 
2 Koothir (Iypasi, karthigai) 11 27.5% 
3 Munpani (Margazhi, Thai) 18 45% 
4 Pinpani (Masi, Pankuni) 6 15% 
5 Elavenil (Chithirai, Vaikasi) 2 5% 
6 Muduvenil (Aani, Aadi) 0 0% 
 
 
Inference 
 Regarding Paruvakaalam among 40 cases, 3(7.5%) cases were reported in 
Kaarkaalam, 11(27.5%) cases were reported in Koothirkaalam, 18(45%) cases were 
reported in Munpanikaalam, 6(15%) cases were reported in Pinpanikaalam ,2(5%) 
cases were reported in ElavenilKaalam  . 
 
Kaar Koothir Munpani Pinpani Elavenil Muduvenil 
7.50%
27.50%
45%
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REFERENCE TO THINAI: 
S.NO. NILAM 
NO. OF 
CASES 
PERCENTAGE 
1 Kurinchi 0 0% 
2 Mullai 0 0% 
3 Marutham 0 0%` 
4 Neithal 40 100% 
5 Paalai 0 0% 
 
 
Inference 
 All  the 40 cases,were reported from surroundings of Chennai which belongs 
to Neithalnilam. This is due to the fact that the study was conducted at Chennai a 
Neithal land and so majority of the cases were from that land.  
 
 
Kurinchi Mullai Marutham Neithal Paalai
0% 0% 0%
100%
0%
THINAI
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                                             UYIR THATHUKKAL 
a)AFFECTED VATHAM: 
S.No. Vatham No. of cases Percentage 
1 Praanan 5 12.5% 
2 Abaanan                    5 12.5% 
3 Vyanan 40 100% 
4 Udhanan 12 30% 
5 Samaanan 40 100% 
6 Naagan 0 0% 
7 Koorman 0 0% 
8 Kirukaran 5 12.5% 
9 Devadhathan 10 25% 
10 Dhananjayan 0 0% 
 
 
Inference: 
 In 40 cases, among 10 types of Vaatham, Praanan were affected in 5 (12.5%) cases, 
Abaanan were affected  in 5 (12.5%)cases,vyanan were affected in 40(100%) cases, 
Udhanan were affected in 12(30%) cases, samaanan were affected in 40(100%) 
cases, kirukaran were affected in 5 (12.5%)cases,  Devadhathan were affected in 10 
(25%) cases repectively  . 
12.50%12.50%
100%
30%
100%
0% 0% 12.50%
25%
0%
VATHAM
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b)   AFFECTED PITHAM 
S.NO.  PITHAM  NO. OF CASES  PERCENTAGE  
1 Anal Pitham 5 12.5% 
2 Ranjaga Pitham 33 82.5% 
3 SaathagaPitham.  0 0% 
4 Prasaga Pitham 40 100% 
    
5 Aalosaga Pitham 0 0% 
  
 
 
INFERENCE: 
Among 5 types of Pitham , Anal pitham were affected in 5(12.5%) cases, 
Ranjaga pitham were affected in 33 (82.5%) cases , Prasaga pitham were affected in 
40 (100%) cases  respectively. 
 
 
12.50%
82.50%
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100%
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PITHAM 
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      c) AFFECTED KABAM 
S.NO. KABAM  NO. OF CASES PERCENTAGE 
1 Avalam bagam 5 12.5% 
2 Kilethagam 5 12.5% 
3 Pothagam 0 0% 
4 Tharpagam.  0 0% 
5 Santhigam 0 0% 
 
 
 
INFERENCE: 
Among 40 cases, Avalambagam and Kilethagam were affected in 5 (12.5%) 
cases respectively. 
 
 
12.50% 12.50%
0%
0%
0%
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UDARTHATHUKKAL 
S.NO. NAME   NO. OF CASES PERCENTAGE 
1 Saaram 40 100% 
2 Senneer 33 82.5% 
3 Oon 10 25% 
4 Kozhuppu 0 0% 
5 Enbu 0 0% 
6 Moolai 0 0% 
7 Vindhu / Naatham 0 0% 
 
 
INFERENCE: 
In Udalthathukkal, Saaram were affected in 40(100%) cases  and  Senneer 
were affected in 33(82.5%) cases and Oon were affected in 10(25%) cases. 
 
100%
82.50%
25%
0% 0% 0% 0%
UDAR THATHUKKAL
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                                             ENVAGAI THERVUGAL 
 
        
INFERENCE: 
Among the Ennvagaithervukal ,Naa were affected in 33(82.5%) cases, Niram 
and Sparisam  were affected in all   40(100%) cases , Malam were affected in 5 cases 
(12.5%) and in Naadi 26 (65%)  cases  were vaatha pitham and  14 (35%) cases were 
Pitha vatham. 
82.50%
100%
0% 0%
100%
12.50%
0%
65%
35%
ENVAGAI THERVUGAL
S.NO. SIDDHA PARAMETERS  NO. OF CASES PERCENTAGE 
1 Naa 33 82.5% 
2 Niram 40 100% 
3 Mozhi 0 0% 
4 Vizhi 0 0% 
5 Sparisam 40 100% 
6 Malam 5 12.5% 
7 Moothiram 0 0% 
8 Naadi   
a)vaatha pitham 26 65% 
b)Pitha vatham 
 
14 
 
35% 
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NEIKKURI 
S.NO. TYPE OF NEER  CHARACTER  NO. OF CASES & 
PERCENTAGE 
1 Vathaneer Aravenaneendal 10(25%) 
2 Pithaneer Aazhipolparavuthal 10(25%) 
3 Kabaneer Muththothunitral 20(50%) 
 
 
 
Inference 
 Among 40 cases, Vathaneerwas observed in 10(25%) cases, Pithaneer was 
observed in 10(25%) cases, Kabaneer was observed in 20(50%) cases. 
 
 
 
Vathaneer
Pithaneer
Kabaneer
NEIKURRI
25% 25%
50%
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100%
50% 47.50%
100%
52.50%
95% 100%
12.50%
47.50%
10% 12.50% 10% 10% 12.50% 15% 25% 5%
22.50%
CLINICAL PROGRESS
Before Treatment After Treatment
 
REFERENCE TO CLINICAL FEATURES 
S.NO Clinical features 
Before Treatment After Treatment 
No.of 
cases 
Percentage 
No.of 
cases 
Percentage 
1 Itching 40 100% 4 10% 
2 Vesicles 20 50% 5 12.5% 
3 Oozing 19     47.5% 4 10% 
4. Papules 40       100% 4 10% 
5 Scaling 21 52.5% 5 12.5% 
6 Erythema 38 95% 6 15% 
7 Hyperpigmentation 40 100% 10 25% 
8 Ulcer 5 12.5% 2 5% 
9 Lichenification 19 47.5% 9 22.5% 
 
 
 
 
 
 
 
Inference 
 The above table reveals that, among all the 40 cases , Itching was reduced in 
36  cases among 40 , vesicles was reduced in 15 cases among 20 , Oozing was 
reduced in 15 cases  among 19 , Papules was reduced in 36 cases  among 40 , scaling 
was reduced in 16 cases among 21 , Erythema was reduced in 32 cases among 38 , 
Hyperpigmentation was reduced in 30 cases among 40 , Ulcer was reduced in 3 cases 
among 5 , Lichenification was reduced in 10 cases among 19 . 
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CASE SUMMARY OF THE PATIENTS 
S.NO OP.NO NAME 
AGE/ 
SEX 
REMARKS 
1 929 Senthil kumar 7 /MC MODERATE 
2 1930 Loshini sahana 7/ FC GOOD 
3 1943 Deva dharsini 3/ FC GOOD 
4 5537 Ragothamman 7/MC GOOD 
5 246 Abdul ajeesh 3/MC MODERATE 
6 897 Soundar rajan 7/MC MODERATE 
7 5358 Karunya 5/FC GOOD 
8 5597 Parthiban 4/MC MODERATE 
9 6219 Yadhavan 5/MC GOOD 
10 5971 Ilanga 6/MC MILD 
11 6659 Mohammed 7/MC MODERATE 
12 6979 Nandhini 5/FC GOOD 
13 7398 Mei iniyavan 3/MC GOOD 
14 7846 Steephan 5/MC GOOD 
15 9560 Niksha 6/FC GOOD 
16 814 Sushil 5/MC MODERATE 
17 1536 Gokul 6/MC GOOD 
18 1622 Karthiga 4/FC MILD 
19 3050 Dharsini 3/FC MODERATE 
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20 3452 Jeevanandham 5/MC GOOD 
21 3753 Krishnan 6/MC GOOD 
22 3889 Gowtham 6/MC GOOD 
23 5085 Sharmila 5/FC GOOD 
24 6106 Ayisha meeran 6/MC GOOD 
25 6399 Swetha 6/FC GOOD 
26 6895 Divya 5/FC GOOD 
27 7692 Harish 5/MC MODERATE 
28 7783 Aakash 5/MC GOOD 
29 8113 Natraj 7/MC GOOD 
30 8647 Naveena 3/ FC GOOD 
31 671 Praveen 7/MC GOOD 
32 2677 Viyaya raj 4/MC MODERATE 
33 3235 Yuva sri 7/FC MILD 
34 3954 Arul raj 3/MC GOOD 
35 5119 Preethi 5/FC GOOD 
36 6786 Archana 6/FC MILD 
37 8523 Santhosh 7/MC GOOD 
38 741 Priya 4/FC GOOD 
39 9622 Prabhu 7/MC MODERATE 
40 9965 Thiru 6/MC MILD 
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LABORATORY INVESTIGATION REPORT OF THE PATIENTS 
SL  
.NO 
 
OP/  
No 
Name 
Age/ 
Sex 
 Haematological analysis    
Urine analysis  
Before treatment  After Treatment  ESR (mm)  Hb (gms %)  
TC  
(cu/mm) 
DC  
TC  
(cu/mm) 
DC  BT  AT   BT  AT  
P %  L% E %  P %  L% E %  ½ 
hr 
1 
hr 
½ 
hr 
1 hr 
BT  AT  
Alb Su g Dep Alb Sug Dep 
1  929 Senthilkumar 7/MC 11800 58 34 8 12000 67 27 5 25 48 12 26 11.9 12.1 N N N N N N 
2  1930 Loshinisahana 7/FC 9900 51 42 7 9800 59 36 4 8 15 6 12 10.7 10.9 N N N N N N 
3  1943 Deva dharsini 3/FC 10900 40 51 9 11000 61 34 5 7 15 6 11 13.2 13 N N N N N N 
4  5537 Ragothamman 7/MC 6400 42 51 7 6800 65 31 4 3 7 3 7 13.6 13.8 N N N N N N 
5  246 Abdul ajeesh 3/MC 11600 70 25 5 11700 49 48 3 15 50 9 24 12.3 12 N N N N N N 
6  897 Soundarrajan 7/MC 10600 60 33 7 11000 58 38 4 5 15 5 15 14 13.9 N N N N N N 
7  5358 Karunya 5/MC 8300 37 56 7 8600 63 32 2 12 22 7 18 12.3 12.5 N N N N N N 
8  5597 Parthiban 4/MC 7400 60 36 4 7300 69 29 2 3 5 3 5 12.1 12.3 N N N N N N 
9  6219 Yadhavan 5/MC 8600 66 29 5 8600 58 40 2 5 15 4 11 11.3 11.4 N N N N N N 
10  5971 Ilango 6/MC 14500 68 26 6 14400 62 35 2 10 21 8 19 11.5 11.8 N N N N N N 
11 6659 Mohammed 7/MC 6600 54 40 6 6800 72 24 4 3 10 4 9 10.7 10.4 N N N N N N 
12 6979 Nandhini 5/FC 8000 62 31 7 8200 68 29 3 12 26 10 21 12 12.2 N N N N N N 
13 7398 Mei iniyavan 3/MC 10500 41 51 8 10400 56 40 4 8 12 5 9 11.2 11.5 N N N N N N 
14 7846 Steephan 5/MC 7900 55 39 6 8200 59 38 3 8 18 8 16 12.9 12.8 N N N N N N 
15  9560 Niksha 6/FC 10100 61 32 7 10000 68 28 4 5 12 5 11 11.9 12.1 N N N N N N 
16  814 Sushil 5/MC 9200 69 25 6 9400 66 31 3 10 21 6 16 10.9 10.8 N N N N N N 
17  1536 Gokul 6/MC 6600 49 43 8 7000 58 38 4 7 18 5 12 11.3 11.5 N N N N N N 
18  1622 Karthiga 4/FC 6800 46 46 8 7100 63 32 5 3 12 4 15 12.3 12.4 N N N N N N 
19  3050 Dharsini 3/FC 9600 57 37 6 9200 67 30 3 16 24 12 20 10.7 10.9 N N N N N N 
20 3452 Jeevanandham 5/MC 6600 51 42 7 6800 54 43 3 3 5 3 6 11.8 12.1 N N N N N N 
 
78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LABORATORY INVESTIGATION REPORT OF THE PATIENTS 
SL .NO  
 
OP/   No  Name  
Age/ 
Sex   
 Haematological analysis    
Urine analysis  
Before treatment  After Treatment  ESR (mm)  Hb (gms %)  
TC  
(cu/mm) 
DC  
TC  
(cu/mm) 
DC  BT  AT   BT  AT  
P %  L% E %  P %  L% E %  ½ 
hr 
1 
hr 
½ 
hr 
1 hr 
BT  AT  
Alb Su 
g 
Dep Alb Sug Dep 
21 3753 Krishnan 6/MC 7000 42 49 9 7400 49 46 5 10 21 8 19 12.2 12.2 N N N N N N 
22 3889 Gowtham 6/MC 7300 48 45 7 7600 57 39 4 3 5 3 6 12 12.1 N N N N N N 
23  5085 Sharmila 5/FC 8300 68 26 6 8200 68 30 2 12 25 9 18 10.8 10.8 N N N N N N 
24  6106 Ayishameeran 6/MC 11600 74 21 5 11400 71 27 2 6 20 8 21 11.8 12 N N N N N N 
25  6399 Swetha 6/FC 7300 53 43 4 7500 56 43 1 20 42 16 35 12.2 12 N N N N N N 
26  6895 Divya 5/FC 6700 65 29 6 6900 58 39 3 5 12 5 12 12.6 12.8 N N N N N N 
27  7692 Harish 5/MC 6900 65 28 7 7100 72 24 4 14 35 8 22 13.5 13.3 N N N N N N 
28  7783 Aakash 5/MC 9600 48 46 6 9800 51 47 2 3 10 4 8 11.6 11.8 N N N N N N 
29  8113 Natraj 7/MC 10200 65 28 7 10000 55 42 3 8 17 5 11 10.7 10.9 N N N N N N 
30  8647 Naveena 3/MC 9500 44 48 8 9100 57 39 4 3 10 3 8 12.4 12.6 N N N N N N 
31 671 Praveen 7/MC 14100 66 29 5 13800 62 36 2 5 10 3 8 11.7 11.9 N N N N N N 
32 2677 Viyaya raj 4/MC 145000 63 33 4 14000 64 34 2 6 10 4 8 11.9 12.1 N N N N N N 
33 3235 Yuvasri 7/FC 7300 50 43 7 7600 58 38 5 8 15 6 12 12 12.2 N N N N N N 
34 3954 Arul raj 3/MC 9800 67 26 7 9500 49 48 3 3 5 3 5 12 12.4 N N N N N N 
35  5119 Preethi 5/FC 8400 57 37 6 8600 54 44 2 14 30 11 28 11.7 11.8 N N N N N N 
36  6786 Archana 6/FC 12500 59 36 5 12400 65 32 3 6 15 4 11 12.9 13 N N N N N N 
37  8523 Santhosh 7/MC 9800 53 38 9 10000 56 39 5 6 18 5 15 10 10.2 N N N N N N 
38  741 Priya 4/FC 8200 59 33 8 8500 59 37 4 13 28 11 23 10.5 10.9 N N N N N N 
39  
 
9622 Prabhu 7/MC 9600 67 26 7 9800 67 30 3 18 33 11 26 12.1 12.4 N N N N N N 
40 9965 Thiru 6/MC 7800 68 24 8 8000 64 31 5 15 28 10 21 10.8 11 N N N N N N 
 
BT – Before Treatment, AT – After Treatment, N - Nil.TC – Total Blood Count, DC – Differential Blood Count, P – Polymorphs, L – Leucocytes, E – Eosinophils  
3ESR – Erythrocytes Sedimentation Rate, mm – Milli meter Hb – Hemoglobin, Alb – Albumin, Sug – Sugar, Dep – Deposits, FE – Few Epithelial cells, FP – Few Pus cells 
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PATIENTS PHOTOS 
BEFORE TREATMENT                AFTER TREATMENT 
 
 
 
 
 
 
OP No. 897    Name: Soundarajan -7/MC  
 
 
 
 
 
 
OP No. 8647    Name: Naveena -3/FC  
 
 
 
 
 
 
 
OP No. 8523    Name: Santosh -7/MC
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63%
25%
12%
RESULT
Good Moderate Mild
RESULTS 
S.NO RESULTS NO.OF CASES PERCENTAGE 
1 Good 25 62.5% 
2 Moderate 10 25% 
3 Mild 5 12.5% 
 
 
 
 
 
 
 
 
 
 
 
Inference 
Among  40 patients ,25(62.5% ) cases showed good improvement , 10 (25% ) 
cases showed moderate improvement , 5 (12.5% ) cases showed mild improvement . 
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DISCUSSION 
Bala karappan  is a common skin disease in paediatric age group. This disease 
mostly resembles Atopic dermatitis in modern system.It is a chronic relapsing pruritic 
inflammatory skin disease in children associated with personal or family  history of 
other atopic dermatitis like asthma, allergic rhinitis . Symptoms of atopic dermatitis 
are dryness, erythema, excoriation, exudation, fissuring, hyperkeratosis, 
lichenification, papulation, scaling and vesiculation .In this study 40 cases are treated 
in OPD  of postgraduate department of Kuzhanthai Maruthuvam in Govt. Siddha 
Medical College, attached to Arignar Anna Hospital of Indian Medicine, Chennai-106 
from 2015-2017. 
The patients were examined on siddha system of diagnosis with  the help of 
modern investigations. The patients are treated with the trial drug Poovarasu Nei 
(Internal) for 28 days.  
 The observations are described here.  
1. Sex Distribution: 
Among the 40 cases 25 patients were male children and 15 patients were 
female children.Mostly male children were  affected. 
2. Age Distribution:  
Among the 40 cases, maximum numbers of patients 52.5% were in the age 
group of 3 to 5 years, 47.5% were in the age group of 6 to 7 years  
3. Socio Economic status  
Among the 40 cases, maximum numbers of patients 60% were in poor status, 
35% were in middle class and 5% were in high class . The highest incidence was 
observed in poor class children due to poor hygienic, mal nutrition , exposure to 
polluted environment lower their immune response , so the poor children are more 
prone to the disease.  
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4. Family History  
               Among the 40 cases, 60% of the patients showed negative family history, 
40% patients showed positive family history. 
5.  Dietary Habits  
             Among the 40 cases, 90% of the cases were mixed diet.10% of cases were 
vegetarians. 
6. According to Paruvakalam  
Among the 40 cases, highest incidence 45% cases were observed in 
Munpanikalam and 27.5% of cases in Koothirkalam.This study shows dryness of the 
skin due to cold climate may cause the skin diseases in this season .  
7. Distribution of Thinai  
 Out of 40 cases, highest incidence  100% of cases were from in Neithal 
thinai.This is due to the fact that the study was conducted at Chennai a Neithal land 
and so majority of the cases were from that land. As per siddha literature kabam   is 
affected  in neithal nilam so it may aggravate the skin diseases.  
8. Uyir Thathukkal  
Vatham  
Among the 40 cases,Vyanan and Samanan was affected in 100% patients 
,Udhanan was affected in 30% of patients, Devadhathan was affected in 25% of 
patients, Abanan was affected in  12.5% of patients and Kirukaran was affected in   
12.5% of patients.Pranan was affected in 12.5% of patients. . 
Pitham 
Among the 40 cases,Prasaga pitham was affected in 40 patients. Anarpitham 
was affected in 12.5% of the patients and ranjaga pitham was affected in 82.5% of 
the patients. Prasaga pitham is responsible for complexion of the skin so it was 
affected in all cases.  
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Kabam 
Out of 40 cases, Kilethagam and Avalambagam was affected  12.5% of the 
patients. 
9. Ezhu Udal Kattugal  
Out of 40 patients Saaram  was affected in  all  the cases, Seneer was affected 
in 33 (82.5%) cases  and Oon was affected in 25% cases.  
10. Ennvagai Thervugal  
Out of 40 patients,Niram and Sparisam were affected in all the cases, Naa   
were affected in 82.5% of cases and Malam were  affected in 12.5% of the patients .In 
this study 65% of patients have Vatha Pitha Naadi and 35% patients have 
PithaVathaNaadi.  
11. Neikuri 
          Among the 40 cases,25% of patients were having Vatha neer, 25% of patients 
were having Pitha neer and 50% of patients were having Kaba neer.  
12. Clinical Features 
Among the 40 patients. 100% of cases have itching, papules, and 
hyperpigmentation 95%  of cases have erythema, 52.5% have scaling, Oozing and 
Lichenification  have 47.5%, 50% have vesicles12.5% have ulcer  . After treatment  
5%  of cases have Ulcer, 10% of cases have Itching, 0ozing and Papules,12.5% cases 
have  Scaling and Vesicles, 15% cases have  Erythema and 22.5% of cases have 
lichenification. 
13. Lab investigation 
Routine examination of blood and urine were done before and after treatment. 
In most of the cases (85%) were having elevated ESR and increased eosinophil count 
and it has decreased after treatment. 
14.Biochemical analysis  
Qualitative analysis of the Poovarasu Nei presence of   iron, which is more 
soluble and readily absorbable from that helps treating children who have associated 
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anaemia. The study also indicates the presence of chloride, flavonoids, glycosides, 
steroids, carbohydrates, triterepnoids, coumarins, phenols, saponins .      
15. Toxicity study of the drug:  
The Acute and Sub-acute toxicity of the trial drug was carried out in Wistar 
albino rats reveals that the drug has no adverse effects, so it is safe to human beings. 
16. Physicochemical analysis:  
Poovarasu Nei:         
Loss on Drying at 105 °C (%) : 4.73 ± 2.54 
Ash value : 0.68  ± 0.33 
pH : 6 
Specific Gravity  : 1.095 
Viscosity at 50
o
C (Pa s) : 16.87 
Refractive index  : 1.52 
Weight per ml (gm/ml) : 1.1 
Iodoine value (mg I2/g) : 139.7 
Saponification Value 
(mg of KOH to saponify 1gm of fat) 
: 248.17 
Total Iron content (mg/ml) : 0.235 
 
17. Pharmacological analysis:  
Pharmacological analysis showed the internal drug has significant Anti- 
histamine activity,Immunomodulator activity. 
18. Statistical Analysis  
 Since the p value is significant in all clinical features.So there is 
significant reducing of clinical features among the patients for the treatment of 
BalaKarappan(Atopic Dermatitis).Hence it is concluded that the treatment was 
effective and significant. 
19. Result 
 Among the 40 patient‟s good improvement is observed in 25 cases (62.5%), 
moderate improvement in 10 cases (25%) and mild improvement in 5cases (12.5%) 
and no adverse events observed clinically during the course of treatment.  
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SUMMARY 
The clinical study was conducted with the trail drug Poovarasu Nei as Internal 
medicine for the disease Bala karappan in children . 40 patients were selected based 
on protocol. The study is conducted after being screened by the screening committee 
and approved by the Institutional  Ethics committee(IEC) of Govt siddha medical 
college, chennai.  Animal studies are carried, Hence, the study is safely executed on 
human volunteer patients and there was no adverse drug reactions noted during the 
study period. 
40 children with Bala karappan diagnosed clinically treated in out patient 
department  of Arignar Anna Hospital of Indian Medicine, Chennai-106.  They were  
under gone laboratory investigation treated with trial drug, observed for clinical 
improvement and any adverse reaction of the drug . 
I like to summarize this clinical study by the following: 
  The efficacies of the trial drug Poovarasu Nei were studied and observed in 
this study. 
 Clinical diagnosis of Bala karappan was done on the basisof clinical features 
described in kuzhanthai maruthuvam (Bala vagadam) and Noi muthal  nadal 
thirattu. 
 The cost of the trial medicines  are low, comparatively economic. These 
drugs are easily available,  and the dosage is also convenient. 
 The potency of the  trial drug reveals that the presence of chloride, Iron, 
flavonoids, glycosides, steroids, carbohydrates, triterepnoids, coumarins, 
phenols, saponins .      
 The physico chemical analysis of the trial drug shows the safe and 
effectiveness of the drug with the following: 
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The pharmacological analysis of the drug reveals that it possesses very good  
acute and chronic anti histamine and immuno modulatory activity. 
Among the 40 cases treated 62.5% cases had shown Good improvement, 25% 
cases had shown Moderate improvement, 12.5% had shown Mild 
improvement.  
Observation made during the clinical study showed that the trial drug was 
clinically effective and has no adverse reaction among children. 
 
 
 
 
 
 
 
  
Loss on Drying at 105 °C (%) : 4.73 ± 2.54 
Ash value : 0.68  ± 0.33 
pH : 6 
Specific Gravity  : 1.095 
Viscosity at 50
o
C (Pa s) : 16.87 
Refractive index  : 1.52 
Weight per ml (gm/ml) : 1.1 
Iodoine value (mg I2/g) : 139.7 
Saponification Value 
(mg of KOH to saponify 1gm of fat) 
: 248.17 
Total Iron content (mg/ml) : 0.235 
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CONCLUSION 
 Bala karappan is a common skin disorder  in children and mainly caused by 
derangement of kabha kuttram followed by vatham and pitham. In this clinical study 
“Poovarasu Nei”was taken as internal drug respectively.The deranged kuttram is 
settled down by the kaippu suvai  and inipu suvai present in the trial medicine 
Poovarasu Nei (Internal medicine) there by the medicine acts as Ethirurai 
maruthuvam to cure the disease.Also,kasa kasa has transquilliser action and 
sadamanjil has Anti depressant action  
Toxicological studies shows no acute  and sub acute toxicity of the drug. The 
drug  has Anti-Histamine and Immunomodulator   activity. 
 The cost of the trial medicines are low. 
 During the clinical study no adverse events were observed.  
The clinical study confirms the efficacy of the trial drugs by reducing the 
clinical signs and symptoms like itching, Papules, Oozing and scaling. . Clinical study 
results found to be Good in 62.5% cases, Moderate in 25% cases, and Mild in 12.5% 
cases.  
The Clinical trial conducted in selected patients was satisfactory and 
encouraging.The trial medicine is effective for Bala karappan in children. Through 
this study, the effectiveness of trial drug is confirmed and re-established by the 
author. 
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ANNEXURE-  I 
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ANNEXURE -II 
Bio Chemical analysis of trial medicine BALA KARAPPAN 
Preparation of sodium carbonate extract 
 2 gm of Poovarasu Nei  sample is mixed with 5gm of sodium carbonate and 
taken in a 100 ml beaker and 20 ml of distilled water is added. The solution is boiled 
for 10 minutes,cooled and then filtered. The filtrate is called sodium carbonate 
extract. 
S.No Experiment Observation  Inference 
Test for acid radicals 
1A. Test for sulphate: 
2ml of the above prepared extract 
is taken in a test tube.to this add 
2ml of 
4 % Ammonium oxalate solution. 
Absence of white 
precipitate 
Absent 
B. 2ml of extract is added with 2ml of 
dilute Hydrochloric acid until the 
effervescence ceases off.Then 2ml 
Barium chloride solution is added. 
Absence of white 
precipitate 
Absent 
2. Test for chloride : 
2ml of extract is added with dilute 
Nitric acid till the effervescence 
ceases.Then 2ml of silver nitrate 
solution is added. 
Presence of white 
precipitate 
Present 
3. Test for phosphate: 
2 ml of the extract is treated with 2 
ml of Ammonium molybdate 
solution and 2 ml of concentrated 
nitric acid. 
Absence of  Yellow 
precipitate 
Absent 
4. Test for carbonate: 
2 ml of the extract is treated with 2 
ml of Magnesium sulphate 
solution. 
Absence of white 
precipitate 
Absent 
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5. Test for sulphide: 
1 gm of the substance is treated 
with 2 ml of concentrated 
Hydrochloric acid. 
Absence of  Rotten egg 
smelling 
Absent 
6. 
 
Test for Fluoride and 
oxalate : 
2ml of extract is added with dilute 
Acetic acid and 2 ml of Calcium 
chloride solution and heated. 
Absence of white 
precipitate 
Absent 
7. Test for Borate : 
2 pinches of the substance is made 
into paste by using Sulphuric acid 
and alcohol (95%) and introduced 
into the blue flame. 
Absence of Green 
tinged flame 
Absent 
TEST  FOR 
BASIC  RADICALS 
8. Test for lead: 
2 ml of the extract is added with 2 
ml of Potassium iodide solution. 
 
Absence of yellow 
precipitate. 
 
Absent 
9. Test for copper: 
One pinch of substance is made 
into paste with concentrated 
Hydrochloric acid in a watch glass 
and introduced into the non-
luminous part of the flame. 
Absence of  Bluish 
green colored flame 
Absent 
10. Test for aluminium: 
To the 2 ml of extract Sodium 
hydroxide solution is added in 
drops in excess. 
Absence of 
whiteprecipitate 
Absent 
11. Test for iron: 
To the 2 ml of extract 2ml of 
Ammonium thiocyanate solution 
and 2ml of concentrated Nitric acid 
is added. 
Presence of Blood red 
colour 
Present 
12. Test for zinc: 
To the 2 ml of extract Sodium 
hydroxide solution is added in 
drops in excess. 
Absence of green 
tinged flame. 
 
 
Absent 
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13. Test for calcium: 
To the 2 ml of extract Ammonium 
oxalate solution solution is added. 
Absence of white 
precipitate 
Absent 
14. Test for magnesium: 
To the 2 ml of extract Sodium 
hydroxide solution is added in 
drops in excess. 
Absence of white 
precipitate 
 
Absent 
15. Test for ammonium: 
To the 2 ml of extract few ml of 
Nessler‟s reagent and excess of 
Sodium hydroxide solution are 
added. 
Absence of white 
precipitate 
 
 
Absent 
16. Test for sodium: 
2 pinches of the substance is made 
into paste by using Hydrochloric 
acid and introduced into the blue 
flame 
Absence of white 
precipitate 
 
 
Absent 
17. Test for mercury: 
2 ml of extract is treated with 2ml 
of Sodium hydroxide solution. 
Absence of Yellow 
precipitate 
Absent 
18. Test for arsenic: 
2 ml of extract is treated with 2ml 
of Silver nitrate solution. 
Absence of white 
precipitate 
Absent 
 
 
19. Test for starch: 
2 ml of extracts treated with weak 
iodine solution. 
Absence of white 
precipitate 
Absent 
20. Test for reducing sugar 
5ml of Benedicts qualitative 
solution is taken in a test tube and 
allowed to boil for 2 minutes and 
added 10 drops of the extract and 
again boiled for 2minutes.The 
colour changes are noted. 
Absence of white 
precipitate 
 
 
Absent 
21. Test for alkaloids : 
2 ml of the extract is treated with 
2ml of Potassium iodide solution. 
Absence of white 
precipitate 
 
 
Absent 
RESULT 
The given sample Poovarasu Nei  contains Chloride, Iron 
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ANNEXURE – III  
PHYSICO CHEMICAL ANALYSIS  
ICP-MS- Heavy Metal Analysis Report 
ICP-MS 
Inductively Coupled Plasma Mass Spectrometry (ICP-MS): ICP-MS is a type 
of mass spectrometry that is highly sensitive and capable of the determination of a 
range of metals and several non-metals at concentration below one part in 1012 (parts 
per trillion). Samples are decomposed to neutral elements in high temperature argon 
plasma and analyzed based on their mass to charge ratios. It is an automated, simple 
and unique quantitative and qualitative analysis. It measures elemental isotopes ratio. 
Procedure 
Digestion of sample is carried out by transforming 2.5 ml of the sample into a 
closed beaker and 5 ml of concentrated HNO3 was added and digested to near 
dryness. 16 M nitric acid was further added each time to the sample and digested until 
the clear solution was obtained. 5ml of 12 M Hydrochloric acid was added to ensure 
complete digestion .The digested solution was cooled to room temperature and made 
to the final volume of 100 ml with deionized water. Sample solutions were then 
filtered through membrane (0.45micron) filter. Finally, the digested samples were 
used for metal analysis using inductively coupled plasma Mass Spectrometry (Perkin 
Elmer DRC-e Model) .Each sample was digested in triplicate. A blank solution was 
also prepared in a similar manner. 
Machine Model: Agilent 7700 ICPMS 
Sample ID: PN 
Element Concentration (mg/L) Upper Limit (mg/L) 
Cadmium (Cd) BDL 
 
0.299 
BDL – Below Detective Level 
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y = 1.686x + 0.228
R² = 0.983
0
1
2
0 0.2 0.4 0.6
Absorbance
PHYSICO CHEMICAL ANALYSIS  
Organoleptic Evaluation  
Parameter Observation 
Color Reddish Brown 
Smell Characteristic Odour 
Touch Oily 
Appearance Translucent 
 
Preparation of standard solution: 
0.2g of ferric ammonium sulphate was dissolved in distilled water containing 
10ml of concentrated hydrochloric acid and the volume was made up to 250ml with 
distilled water 3. From this stock solution 1, 2, 3, 4 & 5ml was pipette out into 5 
different 50ml volumetric flask and 5ml of 10% aq. hydroxyl ammonium chloride 
solution was added and the pH was adjusted between 3 to 5 using 2M sodium acetate 
buffer solution and 4ml of 1, 10-phenanthrolin was added and finally the volume was 
made up to 50ml with distilled water. After 15-20 min. the absorbance was noted at 
515nm. The standard curve of concentration Vs absorbance was plotted. 
Preparation of Test Solution 
0.21g of test sample was taken with 50ml of 6N hydrochloric acid and boiled 
for 2-3 min. Then it was filtered and the volume was made up to 250ml with distilled 
water. From this 5ml of solution was pipette out into 50ml volumetric flask and the 
same procedure was followed as in the preparation of standard solution. After 15-20 
min. the absorbance was noted at 515nm. From the absorbance the corresponding 
concentration was determined by extrapolation of calibration curve. 
  
102 
 
Concentration mg/ml Absorbance 
0.1 0.382 
0.2 0.545 
0.3 0.792 
0.4 0.911 
0.5 1.042 
Test Sample 0.625 
 
Result:  
The amount of iron present in the sample provided for analysis is 0.235 mg/ml 
Physicochemical evaluation 
Project ID  : NRS/AS/0017/01/2017  
Institute  : Govt Siddha Medical College, Chennai 
Sample Name  : PoovarasuNei 
Sample ID   : PN 
Percentage Loss on Drying 
10gm of test drug was accurately weighed in evaporating dish .The sample 
was dried at 105
o
C for 5 hours and then weighed. 
Percentage loss in drying = Loss of weight of sample/ Wt of the sample X 100 
Determination of Total Ash 
3 g of test drug was accurately weighed in silica dish and incinerated at the 
furnace a temperature 400 ºC until it turns white in color which indicates absence of 
carbon. Percentage of total ash will be calculated with reference to the weight of air-
dried drug. 
Total Ash = Weight of Ash/Wt of the Crude drug taken X 100 
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Determination of pH 
Sample being oily in nature the direct litmus evaluation method was adopted 
to check the pH of the sample. 
Determination of specific gravity  
Fill the dry sp. gravity bottle with prepared samples in such a manner to 
prevent entrapment of air bubbles after removing the cap of side arm. Insert the 
stopper, immerse in water bath at 50
O
C and hold for 30 min.  Carefully wipe off any 
oil that has come out of the capillary opening. Remove the bottle from the bath, clean 
and dry it thoroughly. Remove the cap of the side and quickly weigh. Calculate the 
weight difference between the sample and reference standard. 
Determination of Iodine value  
About 20 gm of oil was transferred into Iodine flask. To which 10 ml of 
chloroform  was added and warmed slightly and cooled for 10 minutes. Followed by 
this about 25 ml of Wiji‟s solution was added in the same flask and shaken well. The 
flask was allowed to stand for 30 mins and refrigerated for anhour.T About 10 ml of 
KI solution was added to this and titrated against 0.1 N Sodium thiosulphate solutions 
until the appearance of yellow colour. 1 ml of starch indicator was added and again 
titrated against the sodium thiosulphate solution from the burette. Disappearance of 
blue colour indicates end point. Repeat the above procedure without taking sample 
and note the corresponding reading for blank titration. 
Determination of saponification value  
About 2 gm of test sample was transferred into the round bottomed flask. To 
this about 20 ml of 0.5 N alcoholic KOH solutions was added to the round bottomed 
flask. Repeatthe same procedure with out taking the sample for blank titration . 
Reflux both sample and blank round bottomed flasks for 1 hour. After reflux, allow 
both the round bottomed flasks to cool. Titrate the samples using 0.5 N HCl with 
phenolphthalein indicator. The disappearance of pink indicates the end point.  
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Final Test report 
Parameter Observation 
Color Reddish Brown 
Smell Characteristic Odour 
Touch Oily 
Appearance Translucent 
 
S.No Parameter Mean (n=3) SD 
1. Loss on Drying at 105 °C (%) 4.73 2.54 
2. Total Ash (%)  0.68  ± 0.33 
3. pH  6 
 
S.No Specific Test PoovarsuNei 
1.  Specific Gravity 1.095 
2.  Viscosity at 50oC (Pa s)  16.87  
3.  Refractive index  1.52 
4.  Weight per ml (gm/ml) 1.1  
5.  Iodoine value (mg I2/g) 139.7 
6.  
Saponification Value  
(mg of KOH to saponify 1gm of 
fat) 
248.17 
7.  Total Iron content (mg/ml) 0.235  
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PHYTOCHEMICAL ANALYSIS 
Sample Preparation 
PoovarasuNei (PN) was extracted with hexane  and the extract was subjected 
to the following analysis 
1) Test for alkaloids: 
Mayer's Test: To the extract, 2ml of mayer's reagent was added, a dull white 
precipitate revealed the presence of alkaloids. 
2) Test for coumarins:  
       To 1 ml of extract, 1 ml of 10% sodium hydroxide was added. The presence of 
coumarins is indicated by the formation of yellow color. 
3) Test for saponins:  
       To 1 ml of the extract, 5 ml of water was added and the tube was shaken 
vigorously. Copious lather formation indicates the presence of Saponins. 
4) Test for tannins:  
       To the extract, ferric chloride was added, formation of a dark blue or greenish 
black color showed the presence of tannins. 
5) Test for glycosides- Borntrager’s Test 
Test drug is hydrolysed with concentrated hydrochloric acid for 2 hours on a water 
bath, filtered and the hydrolysate is subjected to the following tests. To 2 ml of 
filtered hydrolysate, 3 ml of choloroform is added and shaken, choloroform layer is 
separated and 10% ammomia solution is added to it. Pink colour indicates presence of 
glycosides. 
6) Test for flavonoids: 
To 0.1ml of the test sample about 5 ml of dilute ammonia solution were been 
added followed by addition of few drops of conc. Sulfuric acid. Appearance of yellow 
color indicates the presence of Flavonoids. 
 
106 
 
7) Test for phenols: 
Lead acetate test: The extract was taken; 3 ml of 10% lead acetate solution was 
added.  A bulky white precipitate indicated the presence of phenolic compounds. 
8) Test for cardial glycosides: 
Keller-Killani Test: Plant extract treated with 2 ml glacial acetic acid containing a 
drop of   FeCl3 .A brown colour ring indicates the presence of positive test. 
9) Test for steroids: 
To the test solution 2ml of chloroform was added with few drops of conc. 
Sulphuric acid (3ml), and shaken well. The upper layer in the test tube was turns into 
red and sulphuric acid layer showed yellow with green fluorescence. It showed the 
presence of steroids. 
10) Test for Quinones:  
The extracts were treated separately with Alc. KOH solution. Appearance of colors 
ranging from red to blue indicates the presence of Quinones. 
11) Test for Cyanins 
A. Aanthocyanin: 
       To 2 ml of the leaf extract, 1 ml of 2N sodium hydroxide was added and heated 
for 5 min at 100
0
C. Formation of bluish green colour indicates the presence of 
anthocyanin. 
B. Betacyanin: 
To 2 ml of the leaf extract, 1 ml of 2N sodium hydroxide was added and heated for 5 
min at 100 Cᵒ.  Formation of yellow colour indicates the presence of betacyanin. 
12) Test for Carbohydrates - Benedict’s test 
To 0.5 ml of test drug about 0.5 ml of Benedic‟s reagent is added. The mixture 
is heated on a boiling water bath for 2 minutes. A characteristic coloured precipitate 
indicates the presence of sugar. 
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13) Test for terpenoids: 
Salkowski test: 5ml of extract was mixed in 2ml of chloroform, and concentrated 
sulphuric acid was carefully added to form a layer.  A reddish brown colouration of 
the interface indicates the presence of terpenoids. 
RESULT ANALYSIS 
PHYTOCOMPONENTS PN 
ALKALOIDS - 
FLAVONOIDS + 
GLYCOSIDES + 
STEROIDS + 
CARBOHYDRATES + 
TRITEREPNOIDS + 
COUMARINS + 
PHENOLS + 
CARDIAC GLYCOSIDES - 
TANNINS - 
SAPONINS + 
PROTEINS - 
ANTHOCYANIN - 
BETACYANIN - 
QUINONES - 
 
+   Indicates positive 
       -   Indicates Negative 
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STERILITY TEST BY POUR PLATE METHOD 
Objective  
The pour plate techniques were adopted to determine the sterility of the 
product. Contaminated / un sterile sample (formulation) when come in contact with 
the nutrition rich medium it promotes the growth of the organism and after stipulated 
period of incubation the growth of the organism was identified by characteristic 
pattern of colonies. The colonies are referred to as Colony Forming Units (CFUs).   
Methodology 
About 1ml of the test sample was inoculated in sterile petri dish to which 
about 15 mL of molten agar 45
o
C were added. Agar and sample were mixed 
thoroughly by tilting and swirling the dish. Agar was allowed to completely gel 
without disturbing it. (about 10 minutes). Plates were then inverted and incubated at 
37
o
 C for 24-48 hours. Grown colonies of organism was then counted and calculated 
for CFU. 
 
Observation 
No growth was observed after incubation period. Reveals the absence of 
specific pathogen 
Result 
No growth / colonies were observed in any of the plates inoculates with the 
test sample. 
Test Specification Result Method 
E-coli Absent Absent As per AYUSH 
specification Salmonella Absent Absent 
Staphylococcus Aureus Absent Absent 
Pseudomonas 
Aeruginosa 
Absent Absent 
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ANNEXURE IV 
ACUTE AND SUB ACUTE TOXICITY STUDY ON POOVARASU NEI 
 
Name Dr. R.BHARATHI SRI 
IAEC SU/CLATR/IAEC/VII/043/2016 
Name of the 
Formulation Poovarasu Nei 
Abbreviation PN 
 
 ACUTE TOXICITY STUDY 
Acute toxicity study of the study drug Poovarasu Nei was carried out as per 
OECD guideline (Organization for Economic Co-operation and Development) 
Guideline-423. 
Animal 
Healthy adult Wistar albino rat weighing between 170-200 g were used for the 
study. The animals were housed in poly propylene cages and were kept in well 
ventilated with 100% fresh air by air handling unit (AHU). A 12 light / dark cycle 
were maintained .Room temperature was maintained between 22 + 2
0 
Cand relative 
humidity 50–65%. They were provided with food (Sai feeds, Bangalore, India) and 
water ad libitum. All the animals were acclimatized to the laboratory for 7 days prior 
to the start of the study. 
The experimental protocol was approved by The Institutional Animal Ethics 
Committee of Sathyabama University, Chennai, Tamil Nadu, India. 
Acute toxicity Study 
Acute toxicity study will be carried out in accordance with OECD guideline 
423 
1
. The animals were fasted overnight with free access to water. The study was 
conducted with single oral dose administration of Poovarasu Nei.  
IAEC SU/CLATR/IAEC/VII/043/2016 
Animal Grouping 
One group consist of 6 female rats were used for this study. The dose utilized 
for evaluation of acute toxicity study is about 2000 mg/kg higher than that of the 
therapeutic dose.  
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Dose Equivalent = 1ml is equivalent to 1.0690 gm 
Animal Grouping 
GROUP I : Animals received Test drug 2000 mg/kg (p.o)  
The animals were fasted overnight (12- 16 hrs) with free access to water. The 
study was conducted with single oral administration of study drugPoovarasu Nei 
2000mg/kg equivalent to 0.4ml (p.o). The animals were observed continuously for 
first 72 h and then 14 days for emerging signs of behavioral changes, body weight 
changes and for mortality. 
Occurrence of toxicity in animals were observed continuously for the first 4 to 
24 h and observed periodically for the next 14 days.  Observation includes the change 
in skin, fur, eyes and mucus membrane. Appearance of C.N.S,C.V.S and A.N.S related 
toxicity such as tremors, convulsions, sedation, steric behavior, respiratory distress, 
cardiovascular collapse, response to sensory stimuli, salivation, diarrhea, lethargy, 
sleep, coma and mortality were observed with special attention. 
Body weight was recorded periodically. At the end of the experiment all 
animals were subjected for gross necropsy and observed for pathological changes. 
SUB-ACUTE TOXICITY STUDY 
Sub-acute toxicity study was carried out as per OECD guidelines Guideline-
407 
2
. 
Animals 
Healthy adult Wistar albino rat weighing between 170-200 g were used for the 
study.  The animals were housed in poly propylene cages and were kept in well 
ventilated with 100% fresh air by air handling unit (AHU). A 12 light / dark cycle 
were maintained .Room temperature was maintained between 22 + 2
o 
Cand relative 
humidity 50–65%. They were provided with food (Sai feeds, Bangalore, India) and 
water ad libitum. All the animals were acclimatized to the laboratory for 7 days prior 
to the start of the study. 
The experimental protocol was approved by The Institutional Animal Ethics 
Committee of Sathyabama University, Chennai, Tamil Nadu, India. 
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IAEC SU/CLATR/IAEC/VII/043/2016 
Animal Grouping 
Animals were divided into three groups of 06 animals each consist of 3 male 
and 3 female rats. 
GROUP I : Animals received saline 5 ml/kg b.w (p.o)             
GROUP II : Animals received low dose of test drug 200 mg/kg (p.o) 
GROUP III : Animals received high dose of test drug 400 mg/kg (p.o) 
The animals were randomly divided into control group and drug treated 
groups for two different doses viz. low dose (200 mg/kg b.w) equivalent to 0.2 ml and 
high dose (400 mg/kg b.w) equivalent to 0.4 ml,p.o per rat. 
The animals were administrated with the study drug once daily for 28 days. 
The animals in group I (control group) received normal saline 5 ml/kg b.w. The 
animals in group II received low dose of Poovarasu Nei 200 mg/kg b.w (p.o) and 
group III received high dose of Poovarasu Nei 400 mg/kg b.w (p.o). 
The rats were weighed periodically and observed for signs of toxicity pertains 
to C.N.S, C.V.S, A.N.S including behavioral changes, food - water intake and 
morphological changes. At the end of 28
th
 day, the animals were fasted for overnight 
with free access to water. On 29
th
 day the animals were sacrificed with excess 
anesthesia. Blood samples were collected from aorta and stored in EDTA 
(ethylenediamine –tetra actate) for Hematological analysis and for serum generation 
for biochemical analysis. 
The vital organs including heart, brain, lungs, spleen, kidneys, liver, stomach, 
testes, and ovary were harvested and carefully examined for gross lesions. The organs 
were preserved in 10% formalin for histopathological assessment and interpretation. 
Hematological analysis 
Blood samples were analyzed using established procedures and automated 
Bayer Hematology analyzer. Parameters evaluated include Packed Cell Volume 
(PCV), Red Blood Cells (RBC) count, White blood cell count (WBC), Platelet Count, 
Hemoglobin (Hb), Mean cell Haemoglobin Concentration (MCHC), Mean Red Cell 
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Volume (MCV), Mean Cell Hemoglobin (MCH), Mean platelet volume (MPV), 
Neutrophils, Eosinophil‟s, Basophils, Lymphocytes and Monocytes.  
Biochemical analysis 
3
 
Serum samples were analyzed for High Density Lipoprotein (HDL), Low 
density Lipoprotein (LDL) , Very low density Lipoprotein (VLDL) , Triglycerides 
(TGL), Total Cholesterol , Blood urea nitrogen (BUN), Creatinine, Albumin, Total 
Protein, Glucose, Uric acid, Aspartate Transaminase (AST), Alanine amino 
Transaminase (ALT) and Alkaline  Phosphatase (ALP) using Mind ray auto analyzer 
model BS 120. 
Histopathological evaluation 
4
 
 Organs included of heart, brain, lungs, spleen, kidneys, liver, stomach, testes 
and ovary. Histological slides of organs were made and observed under the 
microscope.  The pathological observations of cross section of these organs were 
performed on gross and microscopic bases. Histological examinations were performed 
on the preserved tissues with particular emphasis on those which showed gross 
pathological changes. 
Statistical analysis 
The statistical analysis was carried by one way ANOVA (GRAPH PAD 
PRISM 5 computer program). Results were expressed as mean ± standard error .A 
statistical comparison was carried out using the Dunnet‟s test for the control and 
treatment group.  
DRUG DOSING 
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 Fecal Pellet Analysis 
Methodology 
Rats of control and treatment group were allowed to explore to open field on 
clean and sterile Stainless steel tray. The collected pellets were analyzed for 
consistency, color, Shape, Presence of blood cells etc 
 
 
Acute Toxicity Study   Sub-Acute Toxicity Study 
Analysis Group I  
Analysis Group I Group II Group III 
Consistency Soft –Pasty  
Consistency Soft Soft Soft -Pasty 
Shape Oblong 
 
Shape 
Oblong 
 
Round 
ended 
Round ended 
Colour Dark Green 
 
Colour Greenish 
Pale 
Brown 
Pale Brown 
Mucous 
Shedding Absence 
 
Mucous 
Shedding Absence Absence Absence 
Blood Cells Absent  
Blood Cells Absent Absent Absent 
Signs  
 
of Infection None Observed 
 
Signs of 
Infection 
None 
Observed 
None 
Observed 
None 
Observed 
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Muscle Grip Strength Analysis 
The grip strength test is a simple non-invasive method designed to evaluate rat muscle 
force in vivo. Rats of control and drug treated group was allowed to hold the pull bar 
with both the hind limbs firmly then the animal was gently pulled back with the tail 
until the animal lost the grip toward the bar. The procedure was repeated to get the 
average value. Muscle grip ness of the drug treated group was compared to that of the 
control rat to ensure the change in coordination.  
 
 
 
 
 
 
Metabolic Cage for Urine Collection 
Rat of control and treatment group was placed individually in metabolic cage with 
free access to feed and water. Urine dropping from the animal was collected using 
specialized wire mesh system fixed at the base of the cage having provision to trap the 
fecal pellet mixed with urine sample. The collected urine sample was subjected to 
analysis with respect to colour, pH, glucose, ketone bodies, pus and blood cells. 
RESULTS 
Assessment of clinical signs in rats treated with Poovarasu Nei  on Acute toxicity 
study 
Acute 
Parameter Group I 
Clinical Signs Parameters for the 
duration of 14 days 
Test Drug 
2000mg/kg 
Number of animals observed 6 Female  
Lacrimation Absence 
Salivation Absence 
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Animal appearance Normal 
Tonic Movement Absence 
Clonic Movement Absence 
Laxative action Mild 
Touch Response Normal 
Response to Sound Normal Response 
Response to Light Normal Response 
Mobility Normal Response 
Respiratory Distress Nil 
Skin Color Normal 
Stereotype behavior Absence 
Piloerection Absence 
Limb Paralysis Absence 
Posture Normal 
Open field behavior Normal 
Giat Balancing Normal 
Freezing Behaviour Absent 
Sings of Stress and Anxiety None Observed 
Muscular coordination Normal 
Muscle grip Normal 
Sedation Absence 
Social Behavior Normal 
Urine Analysis No Abnormality 
Urine Colour Yellowish 
Urine pH 6 
Urine -Glucose                         Absence 
Urine -Ketones                        Absence 
Urine- Bilirubin                         Absence 
Urine-Blood  Cells       Negative 
Urine - Pus cells Negative 
Mortality Nil 
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Quantitative data on the body weight of rats treated with Poovarasu Nei  in 
Acute toxicity study 
Group I 
Before Treatment Weight in 
Gms 
After Treatment Weight in 
Gms 
Mean 174.3 184.2 
Std. Deviation 1.751 2.927 
Std. Error 0.7149 1.195 
Values are mean ± S.D (n = 6 per group). Statistical significance carried out using one 
way ANOVA followed by Dunnett‟s test. 
Assessment of clinical signs in rats treated with Poovarasu Nei  on Sub-Acute 
toxicity study 
SUB ACUTE 
Parameter Group I Group II Group III 
Clinical Signs Parameters for 
the duration of 28 days 
Control 
Test Drug 
200mg/kg 
Test Drug 
400mg/kg 
Number of animals observed 
3 Males and 
3Females  
3 Males and 
3Females  
3 Males and 
3Females  
Lacrimation Absence Absence Absence 
Salivation Absence Absence Absence 
Animal appearance Normal Normal Normal 
Tonic Movement Absence Absence Absence 
Clonic Movement Absence Absence Absence 
Laxative action Absence Mild Mild 
Touch Response Normal Normal Normal 
Response to Sound 
Normal 
Response 
Normal 
Response 
Normal 
Response 
Response to Light 
Normal 
Response 
Normal 
Response 
Normal 
Response 
Mobility Normal Normal Normal 
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Response Response Response 
Respiratory Distress Nil Nil Nil 
Skin Color Normal Normal Normal 
Stereotype behavior Absence Absence Absence 
Piloerection Absence Absence Absence 
Limb Paralysis Absence Absence Absence 
Posture Normal Normal Normal 
Open field behavior Normal Normal Normal 
Giat Balancing Normal Normal Normal 
Freezing Behaviour Absent Absent Absent 
Sings of Stress and Anxiety None Observed None Observed None Observed 
Muscular coordination Normal Normal Normal 
Muscle grip Normal Normal Normal 
Sedation Absence Absence Absence 
Social Behavior Normal Normal Normal 
Urine Analysis 
No 
Abnormality 
No 
Abnormality 
No 
Abnormality 
Urine Colour Yellowish Yellowish Yellowish 
Urine pH 6 6 6 
Urine -Glucose                         Absence Absence Absence 
Urine -Ketones                        Absence Absence Absence 
Urine- 
Bilirubin                         
Absence Absence Absence 
Urine-Blood  Cells       Negative Negative Negative 
Urine - Pus cells Negative Negative Negative 
Mortality Nil Nil Nil 
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Effect of Poovarasu Nei on Body weight of Rats in Sub-acute toxicity study 
Group I 
Before Treatment Weight in 
Gms 
After Treatment Weight in 
Gms 
Mean 184 195.5 
Std. Deviation 5.177 5.958 
Std. Error 2.113 2.432 
Group II 
Before Treatment Weight in 
Gms 
After Treatment Weight in 
Gms 
Mean 185.7 199.2 
Std. Deviation 7.633 8.681 
Std. Error 3.116 3.544 
Group III Before Treatment 
After Treatment Weight in 
Gms 
Mean 184 194.8 
Std. Deviation 7.294 7.305 
Std. Error 2.978 2.982 
 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females). 
Control and treatment groups were compared statistically using one way ANOVA 
followed by Dunnett‟s test. 
Quantitative data on the food and water intake of rats treated with Poovarasu 
Nei  for 28 days in Sub-acute toxicity study 
GROUP I Food intake Water intake 
Mean 17.42 22.25 
Std. Deviation 3.573 6.437 
Std. Error 1.787 3.219 
GROUP II Food intake Water intake 
Mean 16.25 28.33 
Std. Deviation 1.524 2.211 
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Std. Error 0.7622 1.106 
GROUP III Food intake Water intake 
Mean 17.92 34.25 
Std. Deviation 2.315 2.379 
Std. Error 1.158 1.189 
 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females). 
Control and treatment groups were compared statistically using one way ANOVA 
followed by Dunnett‟s test. 
Effect of Poovarasu Nei  on Haematology profile of rats in sub-acute toxicity 
study. 
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Values are mean ± S.D (n = 6 per group of which 3 males and 3 females). Control and 
treatment groups were compared statistically using one way ANOVA followed by 
Dunnett‟s test. 
Effect of Poovarasu Nei  on Haematology profile of rats in sub-acute toxicity 
study. 
GROUP I 
Lymph        
(%) 
Mon            
(%) 
Neutrophils   
10
3
/mm3 
Eosinophils 
(%) 
Basophils 
(%) 
MPV     
(fl) 
Mean 80.92 3.6 2.5 1.667 0.1667 5.833 
Std. Deviation 6.151 0.9033 0.6033 0.2251 0.4082 1.14 
Std. Error 2.511 0.3688 0.2463 0.09189 0.1667 0.4652 
GROUP II 
Lymph        
(%) 
Mon            
(%) 
Neutrophils   
10
3
/mm3 
Eosinophils 
(%) 
Basophils 
(%) 
MPV     
(fl) 
Mean 75.33 3.017 2.433 1.533 0.3333 5.967 
Std. Deviation 6.904 0.6616 0.7033 0.2251 0.5164 1.054 
Std. Error 2.818 0.2701 0.2871 0.09189 0.2108 0.4302 
GROUP III 
Lymph        
(%) 
Mon            
(%) 
Neutrophils   
10
3
/mm3 
Eosinophils 
(%) 
Basophils 
(%) 
MPV     
(fl) 
Mean 82.98 2.75 2.733 1.55 0.3333 6.167 
Std. Deviation 9.26 1.169 0.7528 0.2881 0.5164 1.104 
Std. Error 3.78 0.4773 0.3073 0.1176 0.2108 0.4507 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females). 
Control and treatment groups were compared statistically using one way ANOVA 
followed by Dunnett‟s test. 
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Effect of Poovarasu Nei  on Serum Bio-chemistry profile of rats in sub-acute 
toxicity study 
GROUP I 
Blood 
sugar  
(mg/dl) 
BUN 
(mg/dl) 
Serum 
creatinine 
(mg/dl) 
Serum 
total 
choleste
rol 
(mg/dl) 
Serum 
triglyceri
des level 
(mg/dl) 
Serum 
HDL 
choleste
rol 
(mg/dl) 
Serum 
LDL 
choleste
rol 
(mg/dl) 
Serum VLDL 
cholesterol 
(mg/dl) 
Mean 77 18.83 0.6833 117 74.33 69.17 31.33 16.45 
Std. 
Deviation 6.066 2.317 0.1722 4.942 5.888 3.545 5.007 2.971 
Std. Error 2.477 0.9458 0.07032 2.018 2.404 1.447 2.044 1.213 
GROUP II 
Blood 
sugar  
(mg/dl) 
BUN 
(mg/dl) 
Serum 
creatinine 
(mg/dl) 
Serum 
total 
choleste
rol 
(mg/dl) 
Serum 
triglyceri
des level 
(mg/dl) 
Serum 
HDL 
choleste
rol 
(mg/dl) 
Serum 
LDL 
choleste
rol 
(mg/dl) 
Serum VLDL 
cholesterol 
(mg/dl) 
Mean 73.83 12.83 0.7 109.9 84 63.67 32.83 13.42 
Std. 
Deviation 8.542 2.483 0.2191 10.62 13.96 10.01 9.239 1.888 
Std. Error 3.487 1.014 0.08944 4.334 5.698 4.088 3.772 0.7709 
 
 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females). Control and 
treatment groups were compared statistically using one way ANOVA followed by 
Dunnett‟s test. 
 
GROUP III 
Blood 
sugar  
(mg/dl) 
BUN 
(mg/dl) 
Serum 
creatinine 
(mg/dl) 
Serum 
total 
cholesterol 
(mg/dl) 
Serum 
triglycerides 
level (mg/dl) 
Serum 
HDL 
cholesterol 
(mg/dl) 
Serum 
LDL 
cholesterol 
(mg/dl) 
Serum 
VLDL 
cholest
erol 
(mg/dl) 
Mean 81.67 14.67 0.8167 126 90.5 67.67 41.67 16.67 
Std. 
Deviation 7.659 3.615 0.1472 11.22 8.55 4.082 10.19 4.517 
Std. Error 3.127 1.476 0.06009 4.582 3.49 1.667 4.161 1.844 
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Effect of Poovarasu Nei  on Serum Bio-chemistry profile of rats in sub-acute 
toxicity study 
GROUP I 
Serum 
total 
protein 
(g/dl) 
Serum 
albumin 
(g/dl) 
(AST)  
(IU/ml) 
(ALT)               
(IU/L) 
(ALP)         
(IU/L) 
Mean 6.35 3.6 102.3 36.5 112 
Std. Deviation 0.9995 0.08944 13.87 7.714 15.47 
Std. Error 0.408 0.03651 5.661 3.149 6.314 
GROUP II 
Serum 
total 
protein 
(g/dl) 
Serum 
albumin 
(g/dl) 
(AST)  
(IU/ml) 
(ALT)               
(IU/L) 
(ALP)         
(IU/L) 
Mean 6.017 3.9 107.3 28.67 158.2 
Std. Deviation 0.7574 0.6899 19 7.174 48.99 
Std. Error 0.3092 0.2817 7.757 2.929 20 
GROUP III 
Serum 
total 
protein 
(g/dl) 
Serum 
albumin 
(g/dl) 
(AST)  
(IU/ml) 
(ALT)               
(IU/L) 
(ALP)         
(IU/L) 
Mean 6.517 3.933 103.2 32.17 126.2 
Std. Deviation 1.023 0.5086 16.53 8.085 14.82 
Std. Error 0.4175 0.2076 6.75 3.301 6.052 
 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females). Control and 
treatment groups were compared statistically using one way ANOVA followed by 
Dunnett‟s test. 
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Organ Gross Observation of rats treated with Poovarasu Nei for 28 days in Sub-
acute toxicity study. 
Treatment Female 
 
 
 
 
 
 
 
 
Treatment Male 
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Quantitative data on absolute organ weight of rats treated with Poovarasu Nei 
for 28 days in Sub-acute toxicity study. 
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Mean 0.7683 5.948 1.617 0.5667 1.483 1.6 1.15 1.833 0.8667 
Std. Deviation 0.05636 0.9834 0.2137 0.1633 0.1472 0.3162 0.501 0.4933 0.4041 
Std. Error 0.02301 0.4015 0.08724 0.06667 0.06009 0.1291 0.2045 0.2848 0.2333 
G
R
O
U
P
 I
I 
H
E
A
R
T
  
  
  
  
  
  
  
  
 
(g
m
s)
 
L
IV
E
R
  
  
  
  
  
  
  
 
(g
m
s)
 
K
ID
N
E
Y
S
 
(g
m
s)
 
S
P
L
E
E
N
 (
g
m
s)
 
B
R
A
IN
  
 (
g
m
s)
 
L
U
N
G
  
  
(g
m
s)
 
S
T
O
M
A
C
H
  
  
  
  
  
  
  
 
(g
m
s)
 
T
E
S
T
E
S
 (
g
m
s)
 
U
T
E
R
U
S
 &
 
O
V
A
R
Y
 (
g
m
s)
 
Mean 0.5917 5.932 1.583 0.5667 1.5 1.533 0.9667 3.6 0.9667 
Std. Deviation 0.1357 0.4362 0.1472 0.1366 0.2191 0.1862 0.3502 0.755 0.2082 
Std. Error 0.0554 0.1781 0.06009 0.05578 0.08944 0.07601 0.143 0.4359 0.1202 
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Mean 0.63 5.487 1.35 0.5 1.45 1.45 0.9333 3.067 0.8 
Std. Deviation 0.1702 0.9404 0.1049 0.1414 0.2074 0.3271 0.3327 0.4726 0.4359 
Std. Error 0.06947 0.3839 0.04282 0.05774 0.08466 0.1335 0.1358 0.2728 0.2517 
 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females) for 
Heart, Liver, Kidney, Brain, Spleen, Lung, Stomach.   Values are mean ± S.D (n = 3 
per group per sex ) for testes , ovary and uterus for Control and treatment groups were 
compared statistically using one way ANOVA followed by Dunnett‟s test. 
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Histopathology of Brain (Female Rat) in Sub-acute toxicity Study 
 
Low Power Magnification 10X 
 
GROUP I         GROUP II   GROUP III 
 
High Power Magnification 40X 
 
GROUP I  GROUP II   GROUP III 
 
Histopathology of Heart (Female Rat) in Sub-acute toxicity Study 
 
Low Power Magnification 10X 
 
GROUP I              GROUP II GROUP III 
High Power Magnification 40X 
 
 
 GROUP I  GROUP II  GROUP III 
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Histopathology of Kidney (Female Rat) in Sub-acute toxicity Study 
 
Low Power Magnification 10X 
 
  GROUP I  GROUP II   GROUP III 
 
High Power Magnification 40X 
 
   GROUP I         GROUP II   GROUP III 
 
Histopathology of Liver (Female Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
 
 
      GROUP I        GROUP II   GROUP III 
 
High Power Magnification 40X 
 
      GROUP I        GROUP II   GROUP III 
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Histopathology of Lung (Female Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
 
 
 
 
  GROUP I  GROUP II   GROUP III 
 
High Power Magnification 40X 
 
 
 
 
 
 
GROUP I  GROUP II   GROUP III 
 
Histopathology of Brain (Male Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
 
  GROUP I  GROUP II   GROUP III 
 
High Power Magnification 40X 
 
 
 
  GROUP I  GROUP II   GROUP III 
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Histopathology of Heart (Male Rat) in Sub-acute toxicity Study 
 
Low Power Magnification 10X 
 
 GROUP I      GROUP II  GROUP III 
 
High Power Magnification 40X 
 
 GROUP I    GROUP II   GROUP III 
 
Histopathology of Kidney (Male Rat) in Sub-acute toxicity Study 
 
Low Power Magnification 10X 
 
  GROUP I     GROUP II             GROUP III 
 
High Power Magnification 40X 
 
  GROUP I    GROUP II  GROUP III 
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Histopathology of Liver (Male Rat) in Sub-acute toxicity Study 
 
Low Power Magnification 10X 
 
 GROUP I     GROUP II      GROUP III 
 
High Power Magnification 40X 
 
  GROUP I  GROUP II   GROUP III 
 
 
Histopathology of Lung (Male Rat) in Sub-acute toxicity Study 
 
Low Power Magnification 10X 
 
 
 
  
  
 
 
 
 
 GROUP I    GROUP II         GROUP III 
 
High Power Magnification 40X 
 
 
   
GROUP I    GROUP II        GROUP III 
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HISTOPATHOLOGY REPORT 
BRAIN  
Arrangement of the neurons appears intact with no sings of degeneration or 
apoptotic changes. No signs of ischemia or lesion were observed in sample belongs to 
group I,II and III. 
HEART  
Appearance of cardiomyocyte was normal with dark nuclear region. The 
nuclei of muscle fibers appear central arrangement. Perfectly -arranged myocardial 
fibers, clear transverse striation and normal structure were observed in samples 
belongs to group I, II and III. 
LUNG 
Light microscopic examination of lung revealed normal alveoli and alveolar 
sac with no signs of infiltration in both control and treated rats. 
STOMACH  
Light microscopic observation stomach reveals normal histology of gastric 
wall composed of normal mucosa, muscularismucosa, submucosa, muscularispropiria 
and adventitia. No signs of ulceration were observed in sample belongs to group I, II 
and III. 
LIVER  
Appearance of hepatic sinusoid and hepatic cord was normal. Hepatocellular 
architecture, including hepatic sinusoid and hepatic cord was normal 
SPLEEN  
Marginal vascular zone radiated in between red and white pulp. No signs of f 
immunological activities. Appearance of LF – lymphoid follicle; PALS – periarterial 
lymphoid sheath was normal with no significant signs of enlargement were observed 
in sample belongs to group I, II and III. 
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KIDNEY  
Appearance of glomerular basement membrane was normal. No evidence of 
lymphocytic infiltrate and inflammation in sample belongs to group I,II and III. 
TESTES  
Histo cytology of testicular tissue shows well differentiated germ cells with 
respect of spermatogonia includes spermatid and sperm were observed in sample 
belongs to group I,II and III. 
UTERUS 
Appearance of endometrium, myometrium and uterine glands was normal. 
Arrangement of stratum basale, functionale and surface epithelium seems normal in 
samples belongs to group I,II and III. 
OVARY  
Histopathological analysis of ovary showing normal corpus luteum (CL) and 
Primordial follicles with few mature ovarian follicles with no signs of abnormality. 
Appearance of antral follicle, primary oocyte and secondary follicles are normal in 
sample belong to group I,II and III. 
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ANNEXURE V 
 
ANTI- HISTAMINE & IMMUNOMODULATOR ACTIVITY OF POOVARASU NEI 
Molecular Docking Study Report 
Name of the Client: Dr. R.BHARATHI SRI  
Purpose: Computational Analysis 
Project ID : NRS/AS/0017/01/2017 
Formulation : Poovarasu Nei 
Indication : DERMATITIS (ECZEMA) / Immuno Modulatory Activity 
Source: Thespesia Populena 
Phytocomponen
ts 
Action Reference 
Thespone Anti histamine http://fulltext.study/download/2548450.pdf 
Mansonone Anti bacterial 
https://www.ncbi.nlm.nih.gov/pubmed/18274
639 
Kaempferol 
Anti 
inflammatory 
https://www.ncbi.nlm.nih.gov/pubmed/27680
587 
 
Compounds / Drug Selected for Docking based on literature 
 Thespone 
 Mansonone 
 Kaempferol 
Receptors / Target protein Selected for Docking 
Name of the Protein PDB code Standard antagonist 
Histamine 1 receptor 3RZE Cetirizine 
TNF alpha 2AZ5 Diclofenac 
IL6 Interleukin 1P9M Diclofenac 
Cyclooxygenase I 3KK6 Ibuprofen 
Cyclooxygenase 2 6COX   Celecoxib 
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Final Docking Result Analysis 
Cyclooxygenase 1 Receptor 
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  10 Ibuprofen 205 PHE 209 PHE 348 TYR 352 LEU 381 PHE 
385 
TYR 387 TRP 
1 9 
Kaempfero
l 205 PHE 209 PHE 
344 
VAL 
348 
TYR 
349 
VAL 352 LEU 375 ASN 
2 5 Mansonone 
349 
VAL 
352 
LEU 385 TYR 387 TRP 518 PHE 523 ILE 
527 
ALA 
2 5 Thespone 
349 
VAL 381 PHE 384 LEU 
385 
TYR 387 TRP 518 PHE 523 ILE 
 
Out of three compound‟s kaempferol has 9 interactions (90%) similar to that 
of the standard ibuprofen hence it has promising COX I inhibition activity similarly 
other two compounds has 50% percentage similar interaction to that of the standard 
ibuprofen hence all three compounds has COX I inhibition activity 
Cyclooxygenase 2 Receptor 
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  5 Celecoxib 54 GLN 55 TYR 56 LYS 57 CYS 67 GLU     
1 2 Kaempferol 35 PRO 38 SER 40 PRO 42 GLN 55TYR 67GLU 68 ASN 
0 0 Mansonone 38 SER 40 PRO 42 GLN 68 ASN 165 VAL 166 LYS 465 GLU 
2 1 Thespone 67 GLU             
 
Out of three compound‟s kaempferol has 2 interaction (40%) similar to that of 
the standard Celecoxib hence it has promising COX 2 inhibition activity similarly 
other compound Thespone  has 20% percentage similar interaction to that of the 
standard hence both compounds has COX 2 inhibition activity. Compound 
mansonone has no COX2 inhibition activity. 
 
 
134 
 
TNF Alpha Receptor 
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  5 Diclofenac 57 LEU 59 TYR 61 GLN 119 TYR 151 TYR   
3 3 Kaempferol 59 TYR 119 TYR 151 TYR       
1 5 Mansonone 57 LEU 59 TYR 61 GLN 119 TYR 151 TYR 155 ILE 
2 4 Thespone 59 TYR 61 GLN 119 TYR 151 TYR     
 
Out of three compound‟s Mansonone has all 5 interactions (100%) similar to 
that of the standard Diclofenac hence it has Excellent TNF alpha inhibition activity 
similarly other two compounds Thespone  has 90% percentage and Kaemferol has 75 
% similar interaction to that of the standard hence all three compounds has promising 
TNF alpha inhibition activity. 
IL 6 Receptor 
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  4 Diclofenac 
66 
LYS 
168 
ARG 169 SER 
172 
GLU       
1 4 
Kaempfero
l 
66 
LYS 67 MET 74 PHE 
168 
ARG 169 SER 
172 
GLU 
176 
SER 
1 4 
Mansonon
e 
66 
LYS 67 MET 
168 
ARG 169 SER 
172 
GLU 
173 
PHE 
176 
SER 
2 3 Thespone 
66 
LYS 67 MET 169 SER 
172 
GLU 
173 
PHE 176 SER   
 
Out of three compound‟s Mansononeand kaempferol has all 4 interactions 
(100%) similar to that of the standard Diclofenac hence it has Excellent IL6  
inhibition activity similarly other compud Thespone  has 75% percentage similar 
interaction to that of the standard hence all three compounds has promising IL 6 
inhibition activity. 
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Histamine 1 Receptor 
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Out of three compound‟s kaempferol has 9 interactions (60%)similar to that of 
the standard Citrazine hence it has promising H1 receptor blocking activity similarly 
other compound Thespone  has 46% percentage similar interaction to that of the 
standard hence both compounds has H1 receptor blocking activity. Compound 
mansonone has no H1 receptor blocking activity. 
Conclusion 
Based on the results of the computational analysis it was concluded that the 
compound‟s such as kaempferol,Thespone and mansonone present in the formulation 
Poovarasu Nei possess significant inhibition of COX 1& 2, Histamine 1,TNF 
alpha and IL 6 inhibition activity there it was concluded that this formulation may 
have promising immuno modulatory activity and may effective against Atopic 
dermatitis. 
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ANNEXURE VI 
BIOSTATISTICAL ANALYSIS 
Treatment for BalaKarappan(Atopic Dermatitis): 
The most popular non parametric statistical tool, namely, McNemar Test 
analysis has been employed to analyses the effectiveness with the help of a 
hypothesis. 
S. 
No 
Clinical Features Before Treatment After Treatment 
n% n% 
1. Itching 40(100) 4(10)** 
2. Vesicles 20(50) 5(12.5)** 
3. Oozing 19(47.5) 4(10)** 
4. Papules 40(100) 4(10)** 
5. Scaling 21(52.5) 5(12.5)** 
6. Erythema 38(95) 6(15)** 
7. Hyperpigmentation 40(100) 10(25)** 
8. Ulcer 5(12.5) 2(6)* 
9. Lichenification 19(47.5) 9(22.5)* 
 
McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
Number of cases: 40 
Inference:  
Since the p value is significant in all clinical features.So there is significant 
reducing of clinical features among the patients for the treatment of 
BalaKarappan(Atopic Dermatitis).Hence it is concluded that the treatment was 
effective and significant. 
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ANNEXURE -VII     
GOVERNMENT  SIDDHA  MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
CLINICAL STUDY ON “POOVARASU NEI ” IN THE TREATMENT OF 
“BALA KARAPPAN’’ (ATOPIC DERMATITIS   IN CHILDREN) 
FORM l - SCREENING AND SELECTION PROFORMA 
1.OP NO:  ................................................................. 
2. NAME:  ………………………………………….  
3. AGE:      ………       4.GENDER: …………....... 
5. F.OCCUPATION: ………………………………..      6.F.INCOME:   
………………… 
7. ADDRESS:    ……………………………………    
…………………………………………………… 
…………………………………………………… 
8. CONTACT NO:    ……………………………………              
 INCLUSION CRITERIA: 
• Age :  3-7 Yrs      Yes / No 
• Itching                        Yes / No 
• Patient having symptoms of erythema,vesicles,oozing.    Yes/No 
• Patient having symptoms of  lichenification                      Yes/No 
• Patients who are willing to undergo  Laboratory  investigation.  
                                          Yes / No 
• Patients who are willing to sign the informed consent stating that he/ she will 
conscientiously  stick to the treatment during 48days but can opt out of the 
trial of his/ her own conscious discretion.     Yes 
/ No 
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EXCLUSION CRITERIA 
(Clinical history) 
History of  scabies 
History of  photo dermatitis 
History of  secondary bacterial infection 
History of furunculosis 
 
ADMITTED TO TRIAL: 
  YES                        NO                 
    If yes,             OPD/IPD                    
 
 
Date:        
Station: 
 
 
 
Signature of the Guide                                                  Signature of the Investigator   
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GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI-600 106 
CLINICAL STUDY ON “POOVARASU NEI ” IN THE TREATMENT OF                                          
“BALA KARAPPAN’’ (ATOPIC DERMATITIS  IN CHILDREN) 
FORM lI -HISTORY TAKING PROFORMA 
 
1. SERIAL NO OF THE CASE: …….   
 2.OP/IP NO: ....................................................  
  
3. NAME: ………………………………………… 
 4. AGE: …….. 
5. GENDER: …….. 
 
5.F. OCCUPATION: ………………………………      
 6.F. INCOME:   …………………. 
. 
7.COMPLAINTS & DURATION:   
 
                                                                                                                                                           
8.PERSONAL HISTORY: 
 
 
9. HISTORY OF PREVIOUS ILLNESS 
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10. BIRTH HISTORY 
 
 
11. DIETARY HABIT:     
             1.Vegetarian              
             2.Non-vegetarian 
 
12. FAMILY HISTORY: 
               Whether this problem runs in family? 
  1. Yes                               2.No         
               If yes, mention the relationship of affected person(s) --------------------- 
               History of previous investigations if any ------------------------------ 
 
 
Date:          
Station                                               
 
 
Signature of the Guide                                            Signature of the Investigator 
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GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
CLINICAL STUDY ON “POOVARASU NEI ” IN THE TREATMENT OF 
“BALA KARAPPAN’’ (ATOPIC DERMATITIS  IN CHILDREN) 
FORM III  CLINICAL ASSESSMENT PROFORMA 
 
1. SERIAL NO: …………………   
2.OP / IP NO: ......................................   
3. NAME: ……………………………   4.AGE: ……     5.GENDER: .................            
GENERAL EXAMINATION: 
Height (cms)                : ………………………….                   
Weight (kg)    : ………………………….                   
Temperature(°F)     : ………………………….                   
Pulse rate(/min)   : ………………………….                   
Heart rate(/min)   : ………………………….                   
Respiratory rate(/min)  : ………………………….                   
Blood pressure(mm/Hg)       : ………………………….           
   Present          Absent 
Pallor  
Jaundice 
Cyanosis 
Lymphadenopathy 
Pedal edema 
Clubbing 
Jugular vein pulsation 
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SYSTEMIC EXAMINATION 
CardioVascular System  : ………………………….                   
 
Respiratory system   : ………………………….                   
 
Gastro-intestinal system  : ………………………….                   
 
Central Nervous System  : ………………………….                   
 
Urogenital system   : ………………………….                   
 
Endocrine System   : ………………………….                   
SIDDHA SYSTEM OF EXAMINATIONS: 
1. THEGI:  [BODY CONSTITUTION]  
1. Vatha udal 
2. Pitha udal 
3. Kaba udal 
4. Thon  
2. NILAM:  [LAND WHERE PATIENT LIVED MOST] 
 1. Kurinji    (Hilly terrain)                                   
 2. Mullai    (Forest range)                       
 3. Marutham    (Plains)                            
4. Neithal     (Coastal belt)             
 5. Paalai  (Arid regions) 
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3. KAALAM: 
1. Kaar kaalam                               4.Pinpani kaalam      
2. Koothir kaalam                           5. Ilavenil kaalam 
3. Munpani kaalam                           6.Muthuvenil kaalam 
4. GUNAM: 
 1.Sathuvam                2.Raasatham             3.Thaamatham 
5. IMPORIGAL (SENSORY ORGANS): 
                                                                        Normal/Affected 
Mei     - ----------------------------------------------- 
Vaai       ----------------------------------------------- 
Kann  -------------------------------------------------------- 
Mukku ------------------------------------------------------- 
Sevi ------------------------------------------------ 
6. KANMENDHIRIYAM (MOTOR ORGANS): 
Kai    ----------------------------------                
Kal    ------------------------------------ 
Vaai  ------------------------------------ 
Eruvai  ---------------------------------- 
Karuvaai  --------------------------------- 
7. KOSANGAL (SHEATH): 
Annamaya kosam ------------------------ 
Pranamaya kosam -------------------------- 
Manomaya kosam ------------------------------- 
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Vignana maya kosam ----------------------------- 
Anandamaya kosam ------------------------------- 
8. UYIR THAATHUKKAL: [THREE HUMORS] (VALI,  AZHAL, IYAM) 
A) VALI 
 Pranan –-------------------- 
Abanan -------------------- 
Samanan --------------------- 
Uthanan ------------------------ 
Vyanan ------------------------- 
Naagan --------------------------- 
Koorman ----------------------------- 
Kirukaran ---------------------------- 
Devathathan ---------------------------- 
Dhananjayan ---------------------------- 
B) AZHAL 
Analakam -------------------- 
Ranjakam --------------------- 
Sathakam ----------------------- 
Prasakam ------------------------ 
Alosakam -------------------------- 
C) IYAM 
Avalambagam ------------------------ 
Kilethagam --------------------------- 
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Pothagam ------------------------------ 
Tharpagam ------------------- 
Santhigam ------------------------------ 
9. SEVEN UDAL THATHUKKAL: (SEVEN SOMATIC COMPONENTS) 
Saram ----------------------- 
Senneer ------------------- 
Oon -------------------------- 
Koluppu ----------------------- 
Enbu --------------------------- 
Moolai --------------------------- 
Sronitham ------------------------- 
10. ENVAGAI THERVU: 
I. NAADI: [PULSE PERCEPTION] 
II. SPARISAM: [PALPATION] 
III. NAA: [TONGUE] 
 IV.NIRAM: [COMPLEXION]   
 1. Vadham         
 2. Pitham 
 3. Kabam 
 V.MOZHI: [VOICE] 
1. High Pitched 
            2. Low Pitched 
 3. Medium Pitched 
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VI.VIZHI: [EYES] 
VII. MALAM: [BOWEL HABITS / STOOLS] 
Niram 
Irugal 
Ilagal 
Others 
 VIII. MOOTHIRAM [URINE EXAMINATION]   
NEERKKURI: 
Niram 
Manam 
Edai 
Nurai 
Enjal 
NEIKKURI 
 
 
Date:      
Station: 
 
 
Signature of the Guide                                        Signature of the Investigator   
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GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF  KUZHANTHAI MARUTHUVAM 
CLINICAL STUDY ON “POOVARASU NEI ” IN THE TREATMENT OF 
“BALA KARAPPAN’’ (ATOPIC DERMATITIS   IN CHILDREN) 
FORM IV : LABORATORY INVESTIGATIONS PROFORMA 
 
1. SERIAL NO OF THE CASE: …………………   
2.OP / IP NO: ......................................   
3. NAME: ……………………………   4.AGE: ……     5.GENDER: .................   
A) BLOOD INVESTIGATIONS: 
BLOOD INVESTIGATIONS BEFORE 
TREATMENT 
AFTER 
TREATMENT 
           Hb ( gm/dL)   
Absolute eosinophil count ( Cells/ul)   
           ESR (mm) ½ hr.   
 1 hr.   
           T.WBC (Cells / Cu.mm)   
Differential 
Count (%) 
Polymorphs   
 Lymphocytes   
 Monocytes   
 Eosinophils   
 Basophils   
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B) URINE INVESTIGATIONS: 
URINE 
INVESTIGATIONS 
BEFORE TREATMENT AFTER TREATMENT 
Albumin   
Sugar   
Deposits   
 
 
 
Date:          
Station: 
 
 
 
Signature of the Guide                     Signature of the Investigator   
 
 
 
 
 
 
 
 
 
 
149 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
CLINICAL STUDY ON “POOVARASU NEI ” IN THE TREATMENT OF                                       
“BALA KARAPPAN’’ (ATOPIC DERMATITIS   IN CHILDREN) 
FORM V: INFORMED CONSENT FORM 
 
“I have read the foregoing information, or it has been read to me. I have 
had the opportunity to ask questions about it  to my satisfaction. 
            I   consent voluntarily to participate my chid in this study and understand 
that I have the   right to withdraw my child from the study at any time without in 
any way it affecting my chid further medical care”. 
"I have received a copy of the information sheet/consent form". 
Date: 
Signature of the participant: 
In case of illiterate participant 
  “I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm 
that the individual has given consent freely.”                                                   
Date: 
Signature of a witness                               Left thumb Impression of the Participant     
(Selected by the participant bearing no connection with the survey team)       
Date:    
Station:                                                                                  
Signature of participant:                                                 
 
Signature of the Guide:                                            Signature of the Investigator:   
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muR rpj;j kUj;Jtf; fy;Y}Hp> nrd;id-106 
mwpQh; mz;zh kUj;Jtkid> nrd;id 
 
ghy fug;ghd; Neha;f;fhd rpj;j kUe;jpd; (G+tuR nea;) 
 
 ghpfhpg;Gj; jpwidf; fz;lwpAk; kUj;Jt Ma;tpw;fhd jfty; gbtk; 
Xg;Gjy; gbtk; Ma;thsuhy; rhd;wspf;fg;gl;LJ. 
        ehd; ,e;j Ma;it Fwpj;j midj;J tpguq;fisAk; Nehahspf;F 
GupAk; tifapy; vLj;Jiuj;Njd; vd cWjpaspf;fpNwd;. 
Njjp:                            ifnahg;gk;: 
,lk;:                            ngah;:  
Nehahspapd; ngw;Nwhh; xg;Gjy; gbtk;  
vd;dplk; ,e;j kUj;Jt Ma;tpd; fhuzj;ijAk;> kUe;jpd; jd;ik 
kw;Wk; kUj;Jt topKiw gw;wpAk;> njhlh;e;J vdJ cly; ,af;fj;ij 
fz;fhzpf;fTk;> mjid ghJfhf;fTk;; gad;gLk; kUj;Jt Ma;Tf;$l 
ghpNrhjidfs; gw;wp jpUg;jp mspf;Fk; tifapy; Ma;T kUj;Jtuhy; tpsf;fpf; 
$wg;gl;;lJ. 
ehd; vdJ Fo;e;ijapd; ,e;j kUj;Jt Ma;tpd; NghJ fhuzk; vJTk; 
$whky;> vg;nghOJ Ntz;LkhdhYk; ,e;j Ma;tpypUe;J vdJ Foe;ijia 
tpLtpj;J nfhs;Sk; cupikia njupe;jpUf;fpd;Nwd;. ehd; vd;Dila 
Rje;jpukhf Njh;T nra;Ak; cupikiaf; nfhz;L Neha;f;fhd rpw;whKl;b nea; 
kUe;jpd; ghpfhpg;Gk; jpwidf; fz;lwpAk; kUj;Jt Ma;tpw;F vd;id cl;gLj;j 
xg;Gjy; mspf;fpNwd;.  
Njjp:                            ifnahg;gk;: 
,lk;:                            ngah;:  
 
Njjp:                            rhl;rpf;fhuh; ifnahg;gk;: 
,lk;:                            ngah;:  
 
cwTJiwj;jiyth; ifnahg;gk;:          Muha;r;rpahsh; ifnahg;gk;: 
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GOVERNMENT SIDDHA MEDICAL COLLEGE, CHENNAI 
CLINICAL STUDY ON “POOVARASU NEI ” IN THE TREATMENT OF 
“BALA KARAPPAN’’ (ATOPIC DERMATITIS   IN CHILDREN) 
FORM VI - WITHDRAWAL FORM 
SI NO: 
OP / IP NO:                                               
NAME: 
AGE / GENDER :                
DATE OF TRIAL COMMENCEMENT: 
DATE OF WITHDRAWAL FROM TRIAL: 
REASONS FOR WITHDRAWAL: 
• Long absence at reporting :                                   Yes/ No 
• Irregular treatment:                                                 Yes/ No 
• Shift of locality :                                                     Yes/No 
• Increase in severity of symptoms:                          Yes/No 
• Development of severe adverse drug reactions:     Yes/No 
 
 
Date:          
Station: 
 
 
Signature of the Guide                                                 Signature of the Investigator 
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GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
CLINICAL STUDY ON “POOVARASU NEI” IN THE TREATMENT OF 
“BALA KARAPPAN’’ (ATOPIC DERMATITIS  IN CHILDREN) 
FORM VII – PATIENT INFORMATION SHEET 
 
Name of Co- Investigator: R.Bharathi sri               
Name of the college:  Govt.Siddha Medical  College, Arumbakkam, Chennai-106. 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL. 
 I,R.Bharathi sri  studying M.D (Siddha) at Govt.Siddha Medical College, 
Chennai,  is doing a clinical trial on „„Balakarappan” – (Atopic dermatitis)in children . 
It is becoming a most common disease, occurring throughout the world. In this regard, 
I am in need to ask you few questions. I will maintain confidentiality of your 
comments and data obtained. There will be no risk of disclosing your identity and no 
physical, psychological or professional risk is involved by taking part in this study. 
Taking part in this study is voluntary. No compensation will be paid to you for  taking  
part in this study. 
           You can choose not to take part. You can choose not to answer a specific 
question. There is no specific benefit for you if you take part in the study. However, 
taking part in the study may be of benefit to the community, as it may help us to 
understand the problem of defaulters and potential solutions. 
             If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internal 
medicine”Poovarasu nei" (Internal medicine) 4 ml once in morning   for 28 days.  
 The information I am collecting in this study will remain between you and the 
Co- investigator (myself). I will ask you few questions through a questionnaire. I will 
not write your name on this form. I will use a code instead. 
The questionnaire will take approximately 20 minutes of your time. 
If you wish to find out more about this study before taking part, you can ask 
me all the questions you want or contact R.Bharathi sri, PG Scholar cum Co- 
investigator of this study, attached to Govt. Siddha Medical College, Chennai-106. 
You can also contact the Member-secretary of Ethics committee, Govt.Siddha 
Medical College, Chennai. 
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muR rpj;j kUj;Jtf; fy;Y}Hp> nrd;id-106
mwpQh; mz;zh kUj;Jtkid> nrd;id 
ghy fug;ghd;  Neha;f;fhd rpj;j kUe;jpd; (G+tuR nea;) 
ghpfhpg;Gj; jpwidf; fz;lwpAk; kUj;Jt Ma;tpw;fhd jfty; gbtk; 
Muha;r;rpahsh; ngau;: kUj;Jth;. uh.ghujp = 
epWtdj;jpd; ngau;:muR rpj;j kUj;Jtf; fy;Y}up>mUk;ghf;fk;>nrd;id-106 
muR rpj;j kUj;Jtf; fy;Y}upapy; gl;lNkw;gbg;G gapd;W tUk; ehd; 
kUj;Jtu; uh.ghujp = ghy fug;ghd;  vd;Dk; Nehapy; kUj;Jt Muha;r;rpapy; 
<Lgl;Ls;Nsd;. 
 ,e;j Neha;;  guk;giuahfTk; xt;thj czTg;nghUl;fis 
cl;nfhs;tjhYk;  xt;thikia Vw;gLj;Jk; nghUl;fspd; Nky; mbf;fb 
cuha;tjpdhYk; cz;lhfpwJ.    
 ,J gutf; $ba Nehay;y. 
 ,e;j Muha;r;rp rk;ge;jkhf rpy Nfs;tpfisf; Nfl;fTk;> Njitahd 
Ma;tfg; gupNrhjidf;F jq;fs; Foe;ijia cl;gLj;jTk cs;Nsd;. 
  ,e;j Muha;r;rpf;F jq;fs; tpUg;gj;jpd; Ngupy; cl;gLk; gl;rj;jpy; 
cs;kUe;ehf G+tuR nea; nea; 4 kpyp gad;gLfpd;wJ. 
 ,e;j kUe;J rpwg;ghf ghz;L Neha;f;fhf mq;fPfupf;fg;gl;l rpj;j 
kUj;Jt E}ypy; $wg;gl;Ls;sJ 
 ,e;j Muha;r;rpapy; jq;fis mDkjpj;j gpwF cq;fSf;F tpUg;gk; 
,y;iynadpy; vg;NghJ Ntz;LkhdhYk; Muha;r;rpapy; ,Ue;J tpyfpf; nfhs;s 
cupik cs;sJ. 
 ,e;j Muha;r;rpf;F rk;ge;jkhf Nehapd; jd;ik gw;wpAk; kw;w 
tpguq;fSf;Fk; Muha;r;rpahsu; kUj;Jtu;: uh.ghujp = (gl;lNkw;g; gbg;ghsu;> 
Foe;ij kUj;Jtj; Jiw) mtu;fis ve;j Neuj;jpYk; njhlu;G nfhs;syhk;. 
ifg;Ngrp vz;: 9597531340. NkYk; ,e;j Muha;r;rpf;F jf;f mDkjpr; rhd;W 
(IEC) ngwg;gl;Ls;sJ. 
 ,e;j;wpYk; ghJfhg;ghd %ypif nghUl;fisf; nfhz;L 
jahhpf;fg;gl;Ls;sJ. gf;f tpisTfis Vw;gLj;jhJ. NkYk; czT Kiwapy; 
kUj;Jtuhy; $wg;gLk; gj;jpak; fhf;FkhW mwpTWj;jgLfpwJ. 
      ,J rk;gjkhd jq;fsJ midj;J tptuq;fSk; ufrpakhf itf;fg;gLk; 
vd cWjp mspf;fpNwd;. 
      ,jpy; gazg;gb Kjypa ve;j cjtpj; njhifAk; toq;fg;glkhl;lhJ. 
,e;j Muha;r;rpapd; NghJ clYf;F NtW ghjpg;G Vw;gLk; gl;rj;jpy; mwpQu; 
mz;zh kUj;Jtkidapy; jf;f rpfpr;ir mspf;fg;gLk;. 
154 
 
அபசி஦ர் சித்த நருத்துயக் கல்லூரி 
அ஫ிஞர் அண்ணா இந்தின நருத்துயநணண சசன்ண஦-106 
கபப்஧ான் ந஥ானா஭ிகள் கணைப்஧ிடிக்க நயண்டின உணவு 
யமிப௃ண஫கள் 
 
உணயில் நசர்க்க நயண்டினணய : 
 ஧ச்ணசகாய்க஫ிகள் 
 கீணபயணககள் 
 திரிநதாைசநச஧ாருட்கள் (ஏ஬ம், நஞ்சள், சபீகம், 
ச஧ருங்கானம், நி஭கு, சுக்கு, சயந்தனம், பூண்டு) 
 ப௃ண஭கட்டினதா஦ினங்கள் 
 ஧மயணககள் 
 தண்ணரீ் 
உணயில் தயிர்க்க நயண்டினணய 
 கபப்஧ான்஧ண்ைங்க஭ா஦யபகு, கம்பு, நசா஭ம், 
யாணமக்காய், ஧ாகற்காய் 
 நீன்யணககள், ப௃ட்ணை, கருயாடு, நகாமிக்க஫ி 
 கத்தரிக்காய் 
 பு஭ி 
 ஊறுகாய்யணககள் 
 அதிகஅ஭வுஉப்பு 
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GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
CLINICAL STUDY ON “POOVARASU NEI” IN THE TREATMENT OF 
“BALA KARAPPAN’’ (ATOPIC DERMATITIS  IN CHILDREN) 
FORM X - ADVERSE REACTION REPORTING FORM 
 
SERIAL NO:                                                                                                           
OP/IP NO: 
NAME:                    AGE:                                                 GENDER: 
DATE OF TRIAL COMMENCEMENT: 
DATE OF OCCURRENCE OF THE ADVERSE REACTION:             
TIME: 
DESCRIPTION OF ADVERSE REACTION: 
 
MANAGEMENT: 
 
 
Date:                                                                              
Station: 
 
Signature of the Guide                                                 Signature of the Investigator   
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DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
DISSERTATION STUDY ON POOVARASU NEI IN 
BALA KARAPPAN(ATOPIC DERMATITIS IN CHILDREN) 
INVESTIGATOR- DR.R.BHARATHI SRI 
ANNA HOSPITAL OPD-CHENNAI-106 
OPNO/DATE: 
Name: 
Age/sex: 
Parent name: 
Address: 
 
Pnone no: 
COMPLAINTS AND DURATION: 
Erythema,itching,papules,oozing,scaling, 
Vesicles,pustules,oedema,ulcer/ 
Lichenification 
SITES: 
STAGE:   ACUTE /  SUBACUTE/ CHRONIC 
MODE OF ONSET:     ACUTE/   CHRONIC 
ECONOMIC STATE: POOR / MIDDLE / RICH 
DIET: VEG/MIXED 
FAMILY HISTORY: 
PAST HISTORY: 
CONTACY ALLERGY/FOOD ALLRGY: 
ON EXAMINATION: 
PALLOR                       
HT                          
WT                        
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CVS 
RS 
OTHERS 
ENVAGAI THERVU: 
NaaMalam 
Niram                                             Moothiram 
MozhiNaadi 
VizhiSparisam   
INVESTIGATION 
 BEFORE TREATMENT AFTER TREATMENT 
Blood 
Tc 
Dc 
Hb 
Esr 
Urine 
Alb 
Sug 
Dep 
Motion 
Ova 
Cyst 
others 
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TREATMENT 
W
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RECURRENCE: 
RESULTS: 
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ANNEXURE -8 
GOVT SIDDHA MEDICAL COLLEGE AND HOSPITAL CHENNAI 
Branch -IV KUZHANTHAI MARUTHUVAM 
PROFORMA OF CASE SHEET FOR BALA KARAPPAN 
OP. No :       Nationality :  
Name :        Religion :  
Age :         Date of Admission :  
Sex :         Date of Discharge :  
Address :        Diagnosis :  
Informant :       Medical Officer :  
 
1. Complaints and duration : 
2. History of present illness : 
3. History of Past illness : 
4. Antenatal history : 
5. Birth history : 
6. Neonatal history : 
7. Developmental history : 
8. Nutritional history : 
9. Immunization history : 
10. Family history : 
11. Socio economic status : 
General examination  
1. Appearance and posture : 
2. Nutritional status : 
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3. Anaemia : 
4. Cyanosis : 
5. Clubbing : 
6. Jaundice : 
7. Lymphadenopathy : 
8. Abdominal distension : 
9. Pedal oedema : 
Vital Signs  
1. Temperature : 
2. Pulse rate : 
3. Respiratory rate : 
4. Heart rate : 
5. Blood pressure : 
Anthropometry  
a. Height : 
b. Weight : 
c .Chest circumference :  
SIDDHA ASPECTS  
Nilam  
1. Kurinji : 
2. Mullai : 
3. Marutham : 
4. Neithal : 
5. Paalai : 
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Paruvakaalam  
1. Kaar : 
2. Koothir : 
3. Munpani : 
4. Pinpani : 
5. Elavenil : 
6. Muthuvenil : 
Poripulangal  
1. Mei : 
2. Vai : 
3. Kan : 
4. Mooku : 
5. Sevi : 
Kanmenthiriyam  
1. Kai : 
2. Kaal : 
3. Vaai : 
4. Eruvai : 
5. Karuvai : 
Uyir thathukkal  
Vadham  
1. Praanan : 
2. Abaanan : 
3. Viyaanan : 
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4. Uthaanan : 
5. Samaanan : 
6. Naagan : 
7. Koorman : 
8. Kirukaran : 
9. Devathathan : 
10. Dhananjeyan : 
Pitham  
1. Analpitham : 
2. Ranjagam : 
3. Saadhagam : 
4. Praasagam : 
5. Aalosagam : 
Kabam  
1. Avalambagam : 
2. Kiletham : 
3. Pothagam : 
4. Tharpagam : 
5. Santhigam : 
Udal  kattugal  
1. Saaram : 
2. Senneer : 
3. Oonn : 
4. Kozhuppu : 
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5. Enbu : 
6. Moolai : 
7. Sukkilam / Suronitham:  
Envagai thervugal  
1. Naadi : 
2. Sparisam : 
3. Naa : 
4. Niram : 
5. Mozhi : 
6. Vizhi : 
7. Malam : 
8. Moothiram : 
MODERN ASPECTS  
1. Respiratory System : 
2. Cardiovascular system : 
3. Gastro intestinal system : 
4. Central nervous system : 
5. Excretory system : 
Signs and Symptoms of Bala Karappan 
Itching: 
Papules: 
Erythema: 
Vesicles: 
Scaling: 
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Oozing: 
Hyperpigmentation: 
Laboratory investigations  
Blood  
TC : 
DC : 
ESR : 
1/2 hr : 
1 hr : 
Hb% : 
Urine  
Albumin : 
Sugar : 
Deposits : 
Investigation - Siddha aspect  
1. Neerkuri  
Niram : 
Edai : 
Manam : 
Nurai : 
Enjal : 
2. Neikuri  
3. Trial Drugs: 
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Poovarasu Nei(Internal) 
          3-7 yrs: 4ml once in the morning 
3.Daily progress  
 
Date Symptoms  Medicine  
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GOVT. SIDDHA MEDICAL COLLEGE AND HOSPITAL, 
        POST GRADUATE DEPARTMENT. CHENNAI. 
          Branch -IV KUZHANTHAI MARUTHUVAM 
ADMISSION - DISCHARGE CASE SHEET 
Name of the Medical Unit: 
IP. NO   : 
Bed no   : 
Ward    : 
Name    : 
Age    : 
Sex   : 
Permanent address : 
Temporary address : 
Informant   : 
S.No 
CLINICALFEATURES  
(Signs and Symptoms) 
During Admission During Discharge 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
 
 
 
 
Occupation  : 
Income  : 
Nationality  : 
Religion : 
Date of Admission: 
Date of discharge: 
Diagnosis  : 
Medicalofficer : 
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